Advertisement

The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders

  • Kinga Czubowicz
  • Henryk Jęśko
  • Przemysław Wencel
  • Walter J. Lukiw
  • Robert P. StrosznajderEmail author
Open Access
Article

Abstract

Bioactive sphingolipids—ceramide, sphingosine, and their respective 1-phosphates (C1P and S1P)—are signaling molecules serving as intracellular second messengers. Moreover, S1P acts through G protein-coupled receptors in the plasma membrane. Accumulating evidence points to sphingolipids' engagement in brain aging and in neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases and amyotrophic lateral sclerosis. Metabolic alterations observed in the course of neurodegeneration favor ceramide-dependent pro-apoptotic signaling, while the levels of the neuroprotective S1P are reduced. These trends are observed early in the diseases’ development, suggesting causal relationship. Mechanistic evidence has shown links between altered ceramide/S1P rheostat and the production, secretion, and aggregation of amyloid β/α-synuclein as well as signaling pathways of critical importance for the pathomechanism of protein conformation diseases. Sphingolipids influence multiple aspects of Akt/protein kinase B signaling, a pathway that regulates metabolism, stress response, and Bcl-2 family proteins. The cross-talk between sphingolipids and transcription factors including NF-κB, FOXOs, and AP-1 may be also important for immune regulation and cell survival/death. Sphingolipids regulate exosomes and other secretion mechanisms that can contribute to either the spread of neurotoxic proteins between brain cells, or their clearance. Recent discoveries also suggest the importance of intracellular and exosomal pools of small regulatory RNAs in the creation of disturbed signaling environment in the diseased brain. The identified interactions of bioactive sphingolipids urge for their evaluation as potential therapeutic targets. Moreover, the early disturbances in sphingolipid metabolism may deliver easily accessible biomarkers of neurodegenerative disorders.

Keywords

Alzheimer’s disease Ceramide Huntington’s disease microRNA Parkinson’s disease Sphingosine-1-phosphate 

Introduction

Aging, which itself influences the central nervous system (CNS) in a relatively subtle manner, creates vulnerable background for the development of devastating disorders. Two of the most widespread neurodegenerative diseases are Alzheimer’s (AD) and Parkinson’s (PD). Dementia affects estimated 47 million people worldwide [1], placing enormous burden on the affected individuals, their families, societies, and healthcare systems. AD is the most common neurodegenerative disorder, responsible for up to 70% of dementia cases [1]. This disease is characterized by the presence of aggregates of pathologically misfolded proteins, including the extracellular senile plaques built mainly of amyloid β (Aβ), a product of proteolytic cleavage of the transmembrane Aβ precursor protein (AβPP) by β- and γ-secretase [2]. Neurons in AD also display cytoskeletal abnormalities that are linked to hyperphosphorylation and aggregation of the microtubule-associated tau protein into intracellular neurofibrillary tangles [3].

Parkinson’s disease is the most frequently occurring movement disease and the second most widespread neurodegenerative disorder after AD [4]. It is estimated that PD affects up to 1% of people over the age of 60 and up to ca. 4% over 85 [5]. PD is characterized by subcortical neurodegeneration, including the characteristic loss of dopaminergic phenotype neurons in substantia nigra pars compacta, loss of dopaminergic striatum innervation, and histopathological aberrations in the form of α-synuclein (ASN)-containing intracellular Lewy bodies (LB)/Lewy neurites (LN) [4]. Disturbances in other neurotransmitter systems (serotoninergic, noradrenergic, and cholinergic) are increasingly being recognized along non-motor symptoms, which—in later stages—may include dementia [6]. Like AD, Parkinsonian neurodegeneration progresses in a stealthy manner, and when clear symptoms appear the dopaminergic neuron population is already decimated [4].

Bioactive Sphingolipids Biosynthesis

Once merely considered structural compounds, bioactive sphingolipids are increasingly implicated as signaling molecules in the brain, and play important roles in aging, neurodegenerative disorders, and the accompanying immune deregulation [7]. Ceramide, ceramide-1-phosphate (C1P), sphingosine, and sphingosine-1-phosphate (S1P) are the best described bioactive sphingolipids regulating stress resistance, proliferation, differentiation, and mature phenotypes of nervous system cells [8, 9]. Sphingolipids have multiple ancillary roles in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis, and intracellular trafficking in the CNS [10, 11]. The sphingolipid rheostat model ascribed these compounds clearly opposite roles in cellular survival signaling: ceramide as a cell death activator, while C1P and S1P promoted survival. The fact that single phosphorylation reaction turns ceramide and sphingosine into their antagonistic counterparts stresses the significance of the precise, successful control of sphingolipid metabolism enzymes [8, 12]. Although the pro- versus anti-survival roles have blurred somewhat in recent years [13], the critical roles of sphingolipid signaling in nervous system function have been confirmed by effects of mutations in their biosynthesis and receptor genes [14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]. The importance of bioactive sphingolipids is also stressed by the accumulating evidence about their involvement in aging and neurodegenerative disorders [8, 25, 26, 27, 28, 29].

The rate of ceramide biosynthesis is controlled by the first step of the pathway’s de novo branch, which is catalyzed by serine palmitoyltransferase (SPT). SPT product dihydrosphingosine is then metabolized by ceramide synthase (CERS) to dihydroceramide, which is subsequently converted by dihydroceramide desaturase (DES or DEGS) to ceramide. Ceramide may be metabolized into sphingomyelin by sphingomyelin synthase (SMS, or SGMS); the reverse reaction (the sphingomyelinase pathway) catalyzed by sphingomyelinases (SMases, SMPDs) is another major ceramide source. Ceramide also serves as a precursor for the production of sphingosine by ceramidases. CERS can perform the opposite reaction, which is third ceramide source, termed the salvage pathway. Sphingosine kinases (SPHK1, SPHK2) phosphorylate sphingosine into S1P in a highly regulated fashion in various cellular compartments; dephosphorylation is carried out by S1P phosphatases (SGPP1 and SGPP2), while S1P can be also hydrolyzed irreversibly into ethanolamine phosphate and hexadecenal by S1P lyase (SGPL) [9]. Activity of the enzyme glucocerebrosidase (GBA) can be another ceramide source [30] with significant links to Parkinson’s disease (see Pt. 'The role of bioactive sphingolipids in Parkinson’s disease').

S1P and Ceramide in Neuronal Survival and Death Signaling

Bioactive sphingolipids employ several mechanisms to exert their influence on intra- and extracellular signaling pathways. Plasma membrane is one of main cellular regions of SPHK activation; S1P and probably C1P can bind cell surface receptors [31, 32]. S1P receptors (S1PR1 to S1PR5) belong to the Edg family and bind Gq, Gi, G12/13, and Rho proteins [31]. While data on the postulated C1P receptor is scarce, all S1PR1 to -5 bind Gi, S1PR2 and -3 bind Gq and all but S1PR1 signal through G12/13 (Fig. 1). Through either S1PR-binding G proteins or through more direct interactions with intracellular enzymes, sphingolipids also modulate signaling events such as cAMP (cyclic adenosine monophosphate), MAPK (mitogen-activated protein kinase), PKC (protein kinase C), PLD (phospholipase D), and PI3 kinase–Akt–PKB (protein kinase B) [35, 36]. The PI3K–Akt pathway is a crucial integrator of metabolic and stress signals engaged in a plethora of physiological and pathological processes ranging from energy metabolism through aging to age-related diseases [8]. Sphingolipids are also structural components of lipid bilayers. Changes in their local concentrations modify membrane properties further modulating signaling events that take part in these membranes.
Fig. 1

Signaling pathways triggered by the cell surface receptors for S1P (S1PRs) and C1P (C1PR).

S1P through its G protein-binding receptors modulates pathways known for their engagement in the regulation of cellular metabolism oxidative/nitrosative stress and death/survival. The depicted examples of S1PR-activated signaling pathways are far from exhausting the spectrum of observed interactions (e.g., S1PR2 inhibits Akt while S1PR3 activates it; iNOS is typically induced by NF-κB, but can also undergo S1P-/C1P-dependent suppression via p38 MAPK [8, 33]). In contrast, C1PR, the cell surface receptor for ceramide-1-phosphate, remains poorly characterized and it is generally not known what part of C1P effects it mediates. According to [34], modified

Ceramide controls not only multiple cell death mechanisms but also cellular senescence, differentiation, and aspects of arborization in neurons [37, 38]. Sphingosine also seems to be engaged in cell death modulation [39]. C1P has been shown to stimulate cellular survival, growth, and may counteract ceramide signaling also through downregulation of acid sphingomyelinase and serine palmitoyltransferase activities [40, 41]. S1P regulates cell viability, neuronal excitability, and arborization [31]. Sphingolipids are also engaged in immune phenomena, which critically alter the fate of brain cells in neurodegenerative disorders [31, 37, 38, 42, 43].

The roles of S1P and ceramide in the survival of brain neurons are far more complex than the antagonism described in the sphingolipid rheostat model (Fig. 2) and dependent on the signaling milieu (see below). However, it is highly probable that the AD-linked changes in the metabolism of bioactive sphingolipids should significantly alter the rates of neurodegeneration.
Fig. 2

The changes in bioactive sphingolipid levels observed in aging and neurodegenerative disorders.

Numerous observations in postmortem brain tissues point to the imbalance in the ratio between the concentrations of the apoptosis inducer ceramide, and the typically anti-apoptotic S1P (see Pts. 'Bioactive Sphingolipids in the Pathomechanism of Alzheimer’s Disease' and 'The Role of Bioactive Sphingolipids in Parkinson’s Disease'). Much fewer works address the problem of physiological brain aging, where the changes appear to be partially gender-specific [44].The asterisk indicates clinical data about S1P in PD is missing; however, in experimental disease models, reduced SPHK activity leading to loss of Akt signaling was observed [45, 46].

In most situations, S1P and ceramide antagonistically signal cell survival or death largely via shared mediators (Fig. 3a, b). Yet more strikingly, both can directly inhibit each other’s synthesis [63, 64]. S1P is classically viewed as an anti-apoptotic agent [65, 66] and has been shown to mediate the actions of numerous anti-apoptotic compounds (Fig. 3b, reviewed in [67]). S1P typically opposes the pro-apoptotic role of ceramide presumably by decreasing oxidative stress and modulating the expressions of pro- and anti-apoptotic proteins of Bcl-2 family (Fig. 3) [47].
Fig. 3

The role of ceramide and S1P in neurodegeneration pathways.

a Ceramide-induced axon loss and neuronal apoptosis. According to [37], modified. b The roles of S1P and SPHKs in the modulation of neuronal death. According to various authors (see text). Both S1P and ceramide(s) exert major part of their opposing influence on cell survival through multi-level modulation of the PI3K–Akt pathway, which integrates sphingolipid-based signals with clues on the metabolic condition of the cell, stress levels, etc. [8, 37, 47]. Moreover, sphingolipid signaling displays links with the transcription factors AP-1 and NF-κB [48, 49, 50, 51, 52], which regulate a plethora of processes including cell death and inflammation. Akt targets FOXO1a, 3a, 4, and 6 are engaged in cell death regulation in human tissues [53, 54]. The prevailing role of elevated ceramide in cell degeneration/death is mediated by multiple signals: inhibition of mitochondrial respiration and increased production of reactive oxygen species [55]; the release of AIF, cytochrome c, or SMAC from mitochondria; the Bcl-2-binding protein beclin1; autophagosomal LC3-II (which binds mitochondrial ceramide to induce lethal mitophagy) [56, 57, 58]. While inhibition of HDAC1 and -2 is engaged in the pro-survival signaling of S1P, the role of HDAC3 is more ambiguous [59, 60, 61, 62]. AIF, apoptosis-inducing factor; AP-1, activator protein-1; aSMase, acid SMase; LC3-II, lipidated microtubule-associated protein 1 light chain 3β; C1P, ceramide-1-phosphate; C1PP, C1P phosphatase; CERS, ceramide synthase; DEGS, dihydroceramide desaturase; ERK, extracellular signal-regulated kinase; FOXO, forkhead box protein O; GSK-3β, glycogen synthase kinase 3β; HDAC, histone deacetylase; Jnk, c-Jun N-terminal kinase; MRC, mitochondrial respiratory chain; NF-κB, nuclear factor κB; PI3K, phosphoinositide 3-kinase; PP2A, protein phosphatase 2A; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; S1PR, S1P receptors; SMAC, second mitochondria-derived activator of caspases; SMase, sphingomyelinase; SPHK, sphingosine kinase; SPT, serine palmitoyltransferase; TRAF2, TNF receptor-associated factor 2

S1P can activate p38, ERK, and block Jnk in various tissues by acting through its surface G protein-coupled receptors [67] (however, S1P influence on Jnk can be more varied [68]) (Fig. 3b). ERK appears to mediate the pro-survival action of S1P [69]. S1PRs also stimulate the anti-apoptotic PI3K-Akt pathway [70], whose disruption in AD may heavily contribute to the disease pathomechanism [71, 72]. The nuclear transcription factors targeted by S1P-sensitive pathways include FOXO3a (inhibited by the PI3K-Akt pathway [70]), AP-1 (a transcription factor receiving input from Jnk/p38/ERK [37, 73] and engaged in the network of mutual co-regulation between sphingolipid-related genes [48, 49, 50]), or NF-κB (nuclear factor κB, through direct interaction between SPHK1 with TNF receptor-associated factor TRAF2, and through S1P acting as TRAF2 cofactor [74, 75]). Moreover, histone deacetylases (HDAC1 and -2) are inhibited through S1P binding [59] and can block NF-κB via its deacetylation [76]. NF-κB influence on cell death may vary depending on the signaling context, immune activation, etc.

Through PI3K-Akt, S1PRs can inhibit GSK-3β (the crucial tau kinase [77]) and the pro-apoptotic protein Bad. In addition, S1P has been shown to inhibit ceramide production by acid sphingomyelinase (aSMase) [63]. However, contrary to the initial view on the clear-cut S1P-vs.-ceramide opposition, in some situations, S1P may actually exert neurotoxic influence—depending on the spatiotemporal control of its production and degradation, or when its concentration reaches too high levels [78]. Moreover, it is necessary to bear in mind the mentioned ambiguous nature of some of S1P’s mediators: AP-1 [79], ERK [80, 81], or NF-κB [82, 83].

The roles of ceramides in cellular homoeostasis reach far beyond just being pro-apoptotic molecules. Loss of physiological ceramide concentrations can lead to structural disturbances in mitochondria and reduced respiration [84]. Ceramides also regulate membrane dynamics, thus influencing other aspects of organellar function and life cycle such as mitochondrial fusion and fission, or vesicular transport [85]. It is also well understood that their (patho)physiological roles are highly dependent on their chain length/CERS isoforms [86, 87]. When signaling apoptosis, ceramides appear to use a spectrum of mediators largely shared with S1P, albeit often in a contrasting way (Fig. 3a). Ceramides lead to dephosphorylation and inactivation of Akt via the protein phosphatase PP2A; this relieves Akt’s inhibitory influence on Bad and GSK-3β [77]. On the other hand, ceramide-associated increase in reactive oxygen species (ROS) leads to the activation of p38 and Jnk and to ERK inhibition [37]. The combined influence of p38, Jnk, and ERK modifies the activities of p53 and AP-1 (c-Fos, c-Jun) transcription factors [88]. Together with Bad and GSK-3β activation, these changes cause mitochondrial alterations and via cytochrome c release and the activities of caspase-2, -3, -5, -8, and -9 may lead to axonal degeneration or neuron death [37]. Ceramides might also directly form pores in the outer mitochondrial membrane, leading to the release of cytochrome c and other proteins [89]. Other mitochondrial mediators of apoptosis known to be released in neurons by ceramides include apoptosis-inducing factor (AIF), the second mitochondrion-derived activator of caspase (Smac), and the stress-regulated endoprotease Omi [56]. Ceramide-induced apoptosis thus involves both caspase-mediated and caspase-independent pathways.

As discussed above, changes in the balance between S1P and ceramide (Figs. 2 and 3) may not only influence apoptosis but also change the regulation of autophagy by the complex interplay between mTOR, beclin, and Bcl-2. S1P-dependent autophagy is thought to be a homeostatic, pro-survival response involved in the clearance of intracellular debris (damaged proteins/dysfunctional organelles) [67]. In AD, autophagy can play critical role in the defense against oxidatively damaged cellular components, and its disturbances may exacerbate Aβ and tau deposition [90, 91]. However, autophagy can also constitute a mode of cell death, where autophagolysosomal degradation of mitochondria is dependent on the interaction between ceramide and LC3-II (lipidated microtubule-associated protein 1 light chain 3β) present on lysosomes [57] (Fig. 3).

Bioactive Sphingolipids in Aging

Bioactive sphingolipids have been investigated in the course of aging and in association with extreme longevity [27, 92, 93]. Centenarians display altered fatty acid pattern in ceramides and glucosylceramides—higher levels of sphingolipid species possibly linked to stress resistance (low oxidation susceptibility due to unsaturated fatty acid content) [27], while increased concentration of sphingomyelins (ceramide precursors) has been observed during aging [94]. Sphingolipids appear to have significant influence on the course of aging; research on lower organism models suggests links between ceramide synthesis and longevity [8, 25, 95, 96, 97]. Importantly, bioactive sphingolipids are capable of influencing the IIS (insulin/insulin-like signaling)–PI3K–Akt, a highly conserved, versatile modulator of metabolism, aging, and stress response (Fig. 3) [98, 99, 100, 101, 102]. IGF-I signaling in the brain has been identified to negatively influence organism longevity also in mammals [103, 104], although some controversies persist [105]. Results obtained in humans appear to support IIS role in aging [106, 107]. IIS seems to redirect the vital resources away from long-term investment in favor of more current needs such as metabolic regulation and cellular survival. This leads somewhat surprisingly to the trophic influence of IIS in the brain [8, 108, 109, 110, 111]. PI3K-Akt signaling regulates SPHKs and S1PRs expression/activity and intracellular sphingolipid transport [112, 113, 114, 115]. In turn, S1P receptors can differentially modulate Akt activity [116, 117, 118]. Ceramide leads to inhibition of Akt-dependent pro-survival signaling [47, 119, 120], while C1P stimulates it [121, 122].

The links between sphingolipids and cellular stress are an extremely important aspect of their potential involvement in aging (Fig. 3) [8, 67]. SPHK1 might inhibit ROS and reduce sensitivity to DNA damage [123]. S1P and ceramides are under positive influence of the stress sensor p53, and faulty ROS control leads to alterations in S1P/ceramide signaling [67, 124, 125, 126]. Even more than in aging, stress and inappropriate stress responses are central elements of the pathomechanism of neurodegenerative disorders.

Bioactive Sphingolipids in the Pathomechanism of Alzheimer’s Disease

The pathogenesis of AD is not yet fully elucidated, and the actual roles of many of the observed disturbances are not clear. Accumulating evidence points to the involvement of bioactive sphingolipids in AD starting from the earliest, prodromal stages [127].

Well-documented mechanisms that induce neuronal and synaptic degeneration in AD brain include the following: oxidative damage, altered redox signaling, mitochondrial dysfunction, glucose hypometabolism/other metabolic stresses, Ca2+ deregulation, and inflammatory response. Many of these pathways are triggered and propagated due to the actions of soluble oligomers of Aβ peptide on neurons and glia. The role of ceramide/S1P was analyzed in the context of these damage pathways as well as the process of amyloidogenesis.

The Interactions Between Ceramide/S1P and AβPP/Aβ Metabolism

Structural roles of sphingolipids in cellular membranes including lipid rafts constitute an important aspect of their engagement in AβPP/Aβ metabolism [128]. Lipid rafts are cholesterol- and sphingolipid-enriched microdomains of the plasma membrane described as signaling platforms [129, 130]. Rafts are strongly associated with Aβ production, and both β- and γ-secretases are enriched in these structures [129, 131, 132]. Lipid rafts also seem to influence Aβ aggregation [133]. In turn oligomeric Aβ42 associates with rafts [134]; Aβ can change membrane fluidity, which may exert a feedback influence on its own production [135].

Rafts are sensitive to fluctuations in sphingolipid levels, leading, e.g., to changed properties of membrane-associated enzymes or receptors. Sphingolipid/ceramide deficiency leads to increased secretion of sAβPPα, the product of non-amyloidogenic cleavage. However, it also leads to enhanced secretion of Aβ42 possibly through modulation of raft-associated proteins and changes in raft membrane properties resulting in altered α- vs. β-cleavage ratio [136]. Exogenous addition of ceramide and elevated endogenous ceramide increased the level of Aβ. C6-ceramide, a cell-permeable ceramide analogue, increased the rate of Aβ biosynthesis by affecting β-cleavage of AβPP. Lipid raft ceramides stabilize BACE1 (β-site AβPP cleaving enzyme 1, a β-secretase) [137]. Additionally, it was shown that synthetic ceramide analogues may also function as γ-secretase modulators that increase Aβ42 production [138]. FTY720 in turn has been demonstrated to reduce hippocampal neuron damage and the resulting learning and memory deficits in a rat model induced by bilateral, stereotactic injection of pre-aggregated Aβ42 into the hippocampus [139]. Some of the neuroprotective effect might be ascribed to mobilization of extrasynaptic, N-methyl-D-aspartate receptors to the synapse (a phenomenon reducing cellular sensitivity to Aβ-induced neurotoxic calcium influx) [140]. Importantly, FTY720 and KRP203 (another SPHK2 substrate that can bind S1PR upon phosphorylation) have been shown to reduce neuronal Aβ generation [141]. However, the relationship between S1P and AβPP metabolism is still obscure, as the compounds used may as well downregulate S1PR-dependent signaling; moreover, FTY720 increased Aβ42 in mice in addition to reduction in Aβ40 [141]. Positive correlation between S1P production by SPHK2 and AβPP processing has been reported [142]. S1P produced by SPHK2 may activate BACE1, thus leading to higher release of Aβ peptides. S1P was shown to specifically bind to full-length BACE1 and to increase its proteolytic activity. The production of Aβ peptides can be reduced in N2a neuroblastoma cells by pharmacological inhibition of sphingosine kinases, homozygous SPHK2 gene deletion, or overexpression of the S1P lyase gene and SGPP1 phosphatase [142]. A shift in SPHK2 subcellular distribution from cytosol to the nucleus was observed to correlate with Aβ deposition in AD brains by Dominguez and collaborators [143]. In turn, Aβ production correlates with low SPHK1 and high S1P lyase protein [144]. Disturbances in S1P observed in AD may not only critically regulate caspase-mediated AβPP cleavage. S1P regulates lysosomal AβPP metabolism in a calcium-dependent manner [145]. S1P is also a pro-secretory molecule, and the dependence of AβPP secretion on S1P signaling has direct potential significance in AD [146]. The regulation of gene expression via S1PRs and through intracellular signaling can also lead to complex changes in cellular metabolism. AβPP modulates this process, as shown in FTY720-treated mice overexpressing mutant (V717I) AβPP. FTY720, which raises significant hopes as a repurposed neuroprotective drug in AD, increased the gene expression of sphingosine kinases (SPHKs), ceramide kinase (CERK), and the anti-apoptotic Bcl-2 in an age-dependent manner [147].

The milieu of the brain affected by AD provides multiple stressors such as ROS and cytokines, which could in turn lead to increased ceramide production (Figs. 3 and 4). Lee et al. [152] showed ceramide-dependent death of oligodendrocytes induced by Aβ. Activation of neutral sphingomyelinase (nSMase) and increase in the level of ceramides was observed. Moreover, it was also shown that suppression of ceramidase activity additionally increased the toxicity of Aβ [152]. In the studies of Jana and Pahan [153] superoxide-mediated activation of nSMase was observed in primary culture of human neurons treated with Aβ1–42. NAPDH oxidase mediated the effect, because gene silencing for the p22phox subunit by antisense oligonucleotides inhibited the apoptosis of neurons induced by Aβ1–42. The authors showed that the use of N-acetylcysteine and the NADPH oxidase inhibitor prevented the generation of ceramides and protected against neuron apoptosis. Similar results were obtained in primary rat cortical neurons treated with Aβ oligomers where an increase in neutral and acid sphingomyelinase activities was observed [63]. In another study, Gomez-Brouchet et al. [154] indicated that exposure to Aβ25–35 induced strong SPHK1 inhibition and ceramide accumulation in neuronal SH-SY5Y cells. In that study, the cell death was prevented by overexpression of sphingosine kinase, whereas downregulation of the enzyme by RNA interference enhanced the cell death. Inhibitors of both SMases and exogenously administered S1P demonstrated cytoprotection in the model. Ayasolla et al. [155] observed that in the primary culture of rat astrocytes treated with TNF-α/IL-1β, followed by Aβ25–35, there is a greater increase in the expression of induced nitric oxide synthase (iNOS) and nitric oxide production (NO) than in TNF-α/IL-1β-only astrocytes. In a glial cell line treated with Aβ25–35 and LPS/IFNγ, an increase in iNOS expression and NO production was observed. These phenomena were accompanied by an increase in the level of ceramides as a result of the activation of nSMase. Similar results were obtained in oligodendrocytes treated with Aβ25–35 and TNF-α, or with C2-ceramide and TNF-α [156]. TNF-α-induced ceramide production was also observed by Martinez et al. [157].
Fig. 4

Changes in brain sphingolipid metabolism and signaling observed in Alzheimer’s disease.

Human postmortem brain material was used by numerous authors to compare the levels of bioactive sphingolipids, mRNAs, proteins, and enzyme activities. In the hippocampus S1P levels, mRNAs for CERK, S1PR1, SPHK1, SPHK2, and SPHK activity are reduced [65, 147, 148]. Lower S1P levels, S1PR1 protein, and SPHK protein/activities were observed along elevated S1P lyase proteins in selected cortical areas and in the hippocampus [65, 144]. Increased ceramide (Cer) and sphingomyelin (SM) levels, mRNAs for ceramide synthases (CERS1, 2), SGPL1, SPTLC2, aSMase, and sphingomyelinase protein and activity were observed in brain cortical areas, while ASAH1, CERK, and CERS6 mRNAs were reduced [148, 149, 150, 151]

The accumulated oligomerized Aβ peptide in AD brain may also promote ceramide formation, as demonstrated both in cell culture [148, 153, 154, 155, 156] and animal models [158]. Imbalance in mRNA expression of enzymes responsible for S1P to ceramide ratio, which potentially might decide of the brain cell fates, is observed from the earliest clinically recognizable AD stages (Fig. 4) [149]. Sphingomyelin hydrolysis stimulated by Aβ appears to be the main source of ceramides in the pathology of Alzheimer’s disease [155, 159, 160], along with de novo synthesis (expression of the de novo enzymes increases gradually during AD progression [149]). Activation of SPT by Aβ peptides has been observed, resulting in neurotoxic increase of ceramide levels via de novo pathway [148, 161]. Aβ induces apoptosis by activating aSMase and nSMase, thereby contributing to the increase in ceramide levels. Senile plaques contain aSMase and nSMase proteins along with high levels of saturated ceramides [63, 162], and aSMase activity is upregulated in human AD brains (Fig. 4) [150]. Examples of genes upregulated by AD also included ceramide synthases CERS1 and CERS2, S1P lyase SGPL1, or serine palmitoyltransferase catalytic subunit SPTLC2, while the acid ceramidase ASAH1, ceramide kinase CERK, or—less obviously—CERS6 were reduced [131, 149]. However, contrary to the abovementioned results, Couttas et al. [28] have found an early loss of CERS2 activity at Braak stage I/II (temporal cortex) to III/IV (frontal cortex, hippocampus). An interesting but underexplored link has been identified between the still obscure physiological AβPP role and sphingolipid metabolism, as AβPP intracellular domain is capable of reducing the expression of SPTLC2, potentially keeping the whole sphingolipid metabolism under negative control [131]. Aβ also disturbs S1P signaling, potentially shifting the balance towards a much more pro-apoptotic state (Figs. 2 and 4) [148]. Aβ can downregulate the genes for SPHKs and diminish the level of S1P as observed in wild-type and AβPP-overexpressing PC12 cells in culture [163]. The study by Couttas et al. [65] showed reduced S1P levels with increasing Braak stage in tissue samples taken from the CA1 region of the hippocampus, or gray and white matter of the inferior temporal gyrus (Fig. 4). AD brains also display upregulated expression of S1P lyase SGPL1 and S1P-metabolizing phosphatases [65, 149]. The studies of Ceccom et al. [144] showed a decrease in immunoreactivity of SPHK1, S1P receptor 1, and an increase in S1P lyase in samples taken from the frontal and entorhinal cortices from human AD brains. However, the complex influence of SPHK2 signaling on cell fate and neurodegeneration is reflected by the study of Takasugi et al. [142] who reported upregulation of SPHK2 activity in AD brain cortex while other authors reported reduction of its activity and mRNA in the hippocampus [65, 147].

Importantly, SPHKs’ roles include engagement in the regulation of inflammation, a phenomenon already exploited in the therapy of relapsing remitting multiple sclerosis [164]. The known engagement of sphingolipids in the modulation of NF-κB signaling by TNF-α [165] and other factors strongly suggests widespread opportunities in this field. Aβ specifically modulates the expression of some S1P cell surface receptors in monocytes [166]. Sphingolipid modulators inhibit the accumulation of mononuclear phagocytes in response to Aβ, leading to proposals of their use as therapeutic agents [166]. In turn, anti-ceramide immunity might also contribute to the disease progression [167].

An important hint about the significance of sphingolipids in AD is the association of apolipoprotein E (ApoE whose polymorphisms are strongly linked to AD risk [168]), with the receptor-mediated signaling of secreted S1P [169]. Moreover, correlation has been observed between SPHK activities/S1P content and ApoE allele (2.5× higher S1P/sphingosine ratio in the hippocampus of ApoE2 vs. ApoE4 carriers) in AD [65]. Sphingolipids might be useful, accessible AD biomarkers [170, 171, 172] and—potentially—therapeutic targets [173].

S1P/Ceramide and the Exosome-Mediated Spread of AD Pathology

Exosomes are sphingomyelin- and ceramide-enriched vesicles created inside the multivesicular endosomes (MVE) and then secreted when MVE membrane fuses with the plasmalemma. Exosomes are engaged in intercellular communication and carry microRNAs (miRNAs), messenger RNAs (mRNAs), and protein- and lipid-based signaling molecules. Vesicles released by Aβ-treated astrocytes contain the pro-apoptotic prostate apoptosis response 4 (PAR-4) protein and cause apoptosis in naive cultures [174]. Rodent exosomes can contain Aβ, BACE1, and presenilins 1 and 2 [175]. Amyloid plaques in the AD brain contain an exosome marker [176]. These results have led to a hypothesis that exosomes might seed Aβ aggregation [177]. However, at least under some circumstances exosomes can also inhibit Aβ oligomerization and promote its microglia-mediated clearance [178]. These results might explain the observed association of exosomes with Aβ as a physiological, neuroprotective phenomenon [179], at least in the healthy tissue. It is also possible that exosomes of various origin (e.g., neuronal vs. astrocyte) might exert opposite influence or that the exosomal membranes might facilitate Aβ aggregation independently of protein-mediated exosomal functions (e.g., Aβ degradation by exosomal insulin-degrading enzyme or neprilysin)—reviewed in [177]. Additionally, exosomes can serve as a vehicle for the extracellular secretion and cell-to-cell transport of ASN and tau protein, potentially further supporting the spread of aggregation pathology [180, 181]. S1P receptor signaling has been implicated in exosomal cargo sorting: activity of the S1PR-regulated Rho family GTPases was necessary for the process, and Gβγ inhibitor blocked it [182]. Exosome secretion can be modulated by the activity of neutral sphingomyelinase 2 (nSMase2) and sphingomyelin synthase 2 (SMS2), suggesting unique roles for these enzymes in AD [178, 183], and additional significance for the disturbed ceramide levels observed in the course of the disease, as discussed above.

The Role of Bioactive Sphingolipids in Parkinson’s Disease

The selective, spatially progressing neurodegeneration observed in PD defies full explanation, although hypotheses have been created that probably successfully identify and describe important aspects of its mechanism [4]. Pathological aggregation of ASN inside neuronal cells is widely associated with PD; ASN might also play some role in AD [184]. ASN binds lipid rafts, and negatively regulates S1PR1 signaling there [130]. Moreover, the relatively recently recognized phenomenon of ASN secretion suggests links with sphingolipid signaling, as the engagement of sphingolipids in neuronal secretory pathways is well documented [7, 146]. ASN may undergo regulated secretion in a number of partially characterized mechanisms [45, 185, 186, 187, 188, 189, 190], possibly leading to the peptide being functionally “addressed” for different destinations, allowing passage of ASN (also oligomeric) into various compartments of recipient cells [191]. This may have high significance for the postulated spread of ASN-induced pathology along anatomical connections [4].

Recent evidence suggests links between sphingolipids and PD although data is relatively less abundant. PD is associated with disturbances in sphingolipid metabolism (Figs. 2 and 5) [192, 195, 196, reviewed in 12]. Lipidomic analysis has shown that the levels of ceramides and sphingomyelins were altered in postmortem PD brain tissue as compared to the control samples (a tendency towards shorter acyl chain) [192]. Findings in body fluids suggest the diagnostic value of sphingolipids in PD [197]. In blood plasma, several saturated ceramides and one unsaturated species were significantly higher in PD [198]. Additionally, some blood ceramide species were higher in PD with dementia than in non-demented PD patients and the levels of several saturated ceramides associated with PD-linked psychiatric complications [198, 199]. Mutations in the SMPD1 gene have been repeatedly confirmed to correlate with PD risk [200, 201, 202, 203, 204]. The expression and activity of SPHK1 are reduced in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced murine model of PD (Fig. 5) [194], which can lead to enhanced ROS as well as BAX and HRK (harakiri) mRNA expression [205]. Importantly, the possible similarities between AD- and PD-linked disturbances of sphingolipid metabolism are not limited to direct regulation of apoptotic signaling; products of S1P degradation have been found to modulate autophagic/lysosomal degradation of both Aβ/AβPP and ASN [206]. Administration of FTY720, a sphingosine analog metabolized in the tissue into a S1P receptor modulator, protected against neurodegeneration and behavioral defects in mouse PD models induced by MPTP, 6-hydroxydopamine, or rotenone—via S1PR1 and probably Akt [194, 207, 208]. In turn, secreted ASN can inhibit S1PR1 signaling and disturb the receptor’s localization in lipid rafts [130]. It is worth mentioning, however, that FTY720 failed to offer protection in a model of PD induced by subacute (5 days) MPTP administration [209].
Fig. 5

Changes in brain sphingolipid metabolism/signaling observed in Parkinson’s disease and its experimental models.

Ceramide synthase (CERS) mRNAs, ceramide (Cer), and sphingomyelin (SM) species were measured in postmortem PD brains by Abbott et al. Increased CERS1 expression was found along with a shift towards shorter ceramide acyl chain lengths in brain regions most affected by the disease, although reduction in total levels of ceramide and sphingomyelin concentration was observed [192]. Reduced sphingosine kinase-1 and -2 (SPHKs) and S1P receptor 1 (S1PR1) expression was observed in the mouse MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced model [46, 193]. The MPTP model also displayed lower protein levels and activity of SPHK1 [193, 194]

The PD-linked changes may exert influence not only on neuronal survival and phenotype, but also potentially on the central mechanisms of PD pathology. Sphingomyelin has been demonstrated to modify the expression levels of ASN [210]. Degradation of overexpressed or otherwise pathologically altered ASN may be dependent on the sphingomyelinase [211]. Pharmacological inhibition of SPHK1/-2 activities in cells treated with low concentrations of MPP+ leads to enhanced secretion of ASN, which may strengthen the significance of the new, still underestimated mechanism of Parkinsonian pathology [45]. Outside the CNS, FTY720 also reduced ASN burden in the enteric nervous system, improving gut motility whose reduction is an early peripheral symptom in PD [212]. Interestingly, pramipexole (a dopamine D2/D3 receptor agonist) reversed SPHK1 inhibition in the MPTP model [194], suggesting further interactions between sphingolipid and dopamine signaling.

Glucocerebrosidase (GBA) is a lysosomal enzyme that produces ceramide from glucocerebroside (glucosylceramide) [196]. GBA deficiency/mutations are among top genetic contributors to the development of PD [196, 213, 214] and are statistically associated with Parkinson’s disease [215, 216], contributing to its early development, rapid progression, and presence of additional psychiatric symptoms [217, 218]. Interestingly, β-glucocerebrosidase activity is reduced in the cerebrospinal fluid (CSF) of PD patients even if they do not carry any GBA1 mutations [219]. Variants in the GBA gene may be highly useful in the prediction of PD course [220]. Accumulation of glucosyl compounds and cholesterol has attracted most attention as the pathomechanism in GBA mutations/deficiency [221], but changes in ceramide levels cannot be excluded as an important contributing factor [214, 222]. The enzyme is important in ASN degradation [223] and appears to protect against ASN aggregation [224]. Additionally, PD patients not carrying the GBA mutation also display elevated glucosylceramides in their plasma [198]. Small-molecule GBA chaperones have been suggested as a possible means of therapy in synucleinopathies [225].

Sphingolipids in Huntington’s Disease and Amyotrophic Lateral Sclerosis

In recent years, data has been accumulating on the engagement of sphingolipids in Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). HD is a neurodegenerative brain disorder involving striatum and cortex and manifesting itself in motor and cognitive disturbances. It is caused by a dominant mutation, a triplet expansion in the huntingtin (HTT) gene. HD appears to disturb sphingolipid metabolism; increased SGPL1 protein has been observed in the cortex and striatum of advanced HD postmortem brains, accompanied by striatal reduction in SPHK1 [226]. Most data, however, has been obtained from animal models. Results suggest, similarly to other neurodegenerative disorders, that imbalance in sphingolipid concentrations and enzyme expression levels occurs in early stages of the disease development [227, 228, 229, 230]. SPTLC1 and CERS1 were reduced in the brains of R6/2 mice [227], a HD model mice transgenic for the first exon of huntingtin harboring ca. 160 CAG repeats [231]. The altered sphingolipid metabolism has also been noted in a variety of other cellular and animal HD models [226], although the changes seem to be less clearly weighted towards cell death than in, e.g., AD [228]. However, the reduced S1P levels observed in R6/2 mice [226] appear to be a relevant potential therapeutic target, as FTY720 has been demonstrated to improve neuronal activity, reduce brain atrophy, improve motor function, and increase R6/2 animal survival [232]. Moreover, S1PR agonists increased huntingtin phosphorylation and reduced its aggregation [232, 233]. FTY720 also increased the levels of brain-derived neurotrophic factor (BDNF) levels and mitigated the upregulation of NF-κB, iNOS, and TNF-α that would otherwise lead to the potentially neurotoxic activation of astrocytes; FTY720 thus preserved synaptic plasticity and memory in R6/1 mice (another model with lower number of glutamine repeats in the first huntingtin exon) [234]. The S1PR5 stimulator A-971432 preserved blood-brain barrier integrity in R6/2 mice [233]. These results have led to proposal of S1P-modulating therapy of HD [235].

ALS is a neurodegenerative disorder encompassing motor neuron degeneration, muscle wasting, and paralysis, characterized by severe deregulation of metabolism, including lipid metabolism [236]. Ceramides and their glucosyl and lactosyl derivatives are increased in ALS patient spinal cords [237]. SOD mutant mouse model of ALS displays disturbances in the expression of genes related to immune regulation, exosomal secretion, or lysosomes. Importantly, disturbed levels of ceramides and sphingosine were noted to correlate with disease severity along with the expression of SPHK1, or SGPP2 and sphingolipids—sphingosine and ceramides (d18:1/26:0) [238]. Increased glucosyl ceramide synthase (GCS) expression might hamper normalization of oxidative metabolism and motor recovery [236]. Also in this case, FTY720 improved neurological scores and survival in SOD mutant mice [239]. It modified the mRNA expression of, e.g., iNOS (reduced by the treatment), ARG1 (increased), BDNF (increased), and interleukin genes (IL-1β reduced, IL-10 increased), despite administration starting in the symptomatic phase [239].

MicroRNA Signaling and Bioactive Sphingolipids in Neurodegenerative Disorders

miRNAs are increasingly viewed as central regulators of neuronal homoeostasis, and their causal roles in neurodegenerative disorders are rapidly gaining attention. Deregulation of miRNA-based gene expression control may be a novel disease mechanism, but also delivers potentially valuable biomarkers of its development [240, 241, 242]. Considerable research interest has been generated concerning the role of miRNAs in the neuropathology of bioactive sphingolipids in several progressive age-related human neuropathological diseases, and especially how specific miRNAs may contribute to the dynamic molecular-genetic processes involving aberrant ceramide/C1P/S1P metabolism in both AD and PD. In humans, miRNAs are a family of 18–22 nt single-stranded RNAs that posttranslationally interact with, and regulate, the expression of mature mRNAs. Single upregulated miRNA can target multiple mRNAs to reduce their expression, and multiple miRNAs can target a single mRNA [243, 244, 245]. Whenever progressive neurodegeneration is encountered in central nervous tissues undergoing pathological change, progressive neuronal atrophy and brain cell death the NF-κB-sensitive, pro-inflammatory and potentially pathogenic miRNA species such as miRNA-34a, miRNA-146a, miRNA-155, and several others have been shown to be abundant (and readily detectable by hybridization methodologies) in the cytoplasm of degenerating neurons, as well as in both the extracellular fluid (ECF) and CSF, which is contiguous with ECF. While these miRNAs are normally required for the homeostatic operation of brain cellular and membrane-signaling functions, their upregulation and persistence in deteriorating nervous tissues and the nature of their interaction with biological membranes is associated with, and indicative of, the propagation and spreading of neurodegenerative disease. These miRNAs may be a diagnostic tool for the cytoplasmic status of brain cells at risk for neurodegeneration [241, 242, 243].

In turn, the upregulated microRNAs such as miRNA-34a, miRNA-146a, and miRNA-155 appear to antagonize both individual mRNAs and small families of functionally related mRNAs and, in doing so, affect entire systems of CNS-membrane-relevant genes and plasma membrane processes. Indeed, overexpression of miRNA-34a, miRNA-146a, and/or miRNA-155 have been shown to affect the expression of a large number of genes normally involved in glucose metabolism, innate-immune regulation, membrane integrity, normal vascular function and endothelial cell permeability, oxidative phosphorylation, synaptic plasticity, and exosome generation, encapsulation, and release. All of these processes have been shown to be altered in AD- and PD-affected brain cells and tissues [177, 244, 245, 246, 247, 248, 249, 250]. Examples of target mRNAs include [244, 245, 248]:
  • Immune regulators such as NF-κB, interleukins 4 and 17a, interleukin-1 receptor-associated kinase-1 (IRAK-1), or complement factor-H (CFH)

  • Neuronal activity/synaptic plasticity/scaffold genes such as glutamate receptor genes NR2A, GluR1, synaptobrevin 2, and synaptotagmin 1

  • Genes coding for glycolysis and oxidative phosphorylation proteins such as succinate dehydrogenase complex C, ubiquinol-cytochrome c reductase binding protein and ubiquinol-cytochrome c reductase complex III subunit VII (UQCRB and UQCRQ, respectively), or phosphofructokinase-1

  • Amyloidogenesis-linked genes such as the membrane protein tetraspanin 12 (TSPAN12), or the master postsynaptic membrane-organizing ankyrin-cytoskeletal protein SHANK3

Put another way, specific pathology-linked miRNAs appear to regulate a large number of plasma membrane-resident and plasma membrane-organizing components whose character is defined by sphingolipid composition, turnover, and metabolism.

Many CNS-abundant miRNAs have, in addition, important regulatory functions in the expression of enzymes involved in the generation of ceramide, sphingosine, C1P, S1P, and/or their receptors, both in healthy brain aging and in neurological disease. For example, the pro-inflammatory and rapidly induced NF-κB-regulated miRNA-155 (encoded in humans at chr 21q21.3) has been shown to regulate biosynthesis of the S1PR1 which functions in the amelioration of pathogenic inflammation in systemic autoimmune disease [246, 247, 248, 251]. Interestingly, a five-member cluster of miRNAs encoded on human chromosome 21 that includes let-7c, miRNA-99a, miRNA-125b, miRNA-155, and miRNA-802 may help explain the complex phenotypic diversity of trisomy 21 (Down’s syndrome; DS) and the strong linkage between DS and the aberrant sphingolipid and ceramide metabolism associated with trisomy 21 (DS) neuropathology [252, 253, 254]. Interestingly, some of the most recent brain biolipid research describes the association between neurotoxins secreted by the human gastrointestinal (GI) tract microbiome and inflammatory neurodegeneration of nervous tissues, a complex pathogenic process that is certain to involve CNS sphingolipid composition, their organization, and interactive metabolism [255, 256].

As mentioned earlier, sphingolipids are key regulators of exosomal secretion. Their roles include exosome formation, encapsulation, and miRNA shuttling across the plasma membrane [257]. Exosomes and other extracellular vesicles secreted into the extracellular space from both neuronal and glial cells are enriched with the sphingolipid ceramide, as well as other more complex glycosphingolipids such as gangliosides, and may also be enriched in various species of pathogenic or “communicating” miRNAs [177, 243, 244, 245]. Such exosomal vesicle-bound miRNAs: (a) should be reflective of the sphingolipid and miRNA composition of the brain cell cytoplasm from which they were originally derived; (b) may serve the role as a novel form of intercellular communication among brain cells; (c) may carry selective miRNA ‘cargos’ that regulate both bioactive sphingosine/S1P and ceramide/C1P metabolism as well as other miRNA-mRNA targets in adjacent cells; (d) have been implicated in the inter-neuronal “spreading” of pathogenic signals via “paracrine” and related secretory effects in the diseased and neuro-degenerating brain; (e) have considerable potential for being clinically useful as a predictor and non-invasive diagnostic marker for AD and/or PD; and (f) may provide a “molecular-genetic” signature for a defined group of miRNAs associated with a particular neurological disease [177, 243, 244, 245, 246, 247, 248].

Recently, data on the engagement of miRNA-based gene regulation in HD and ALS begun to accumulate. Postmortem HD cortex samples from Brodmann’s area 4 reveal disturbed miRNA expression (reduced miR-9, miR-9*, miR-29b, miR-124a, miR-132) that might stem from loss of huntingtin-transcription factor interaction in neuronal cells [258]. Numerous deregulated circulating miRNAs have been found in HD cases and might reflect not only the ongoing neurodegeneration but also altered communication with the periphery [259]. Links between altered miRNAs and perturbations in apoptotic and cell cycle signaling have been proposed as a possible mechanism of cell loss in HD [260]. The R6/2 mouse HD model displays reduction in miRNA-34a-5p, a member of miRNA-34 family that is engaged in p53- and SIRT1-dependent modulation of cell cycle, senescence, and apoptosis [261]. A series of mouse models with various numbers of CAG repeats in the huntingtin gene has shown a repeat number- and brain part-dependent alteration in miRNA transcriptome (including miRNAs engaged in neuronal development/survival [262]). Altered miRNA levels in blood plasma and CSF have been proposed as HD biomarkers [263, 264].

The engagement of microRNAs in the pathology not only of neurons but also muscles is relatively better characterized in ALS [265]. A high-throughput next-generation sequencing project has identified reduction in the blood levels of 38 miRNAs in sporadic ALS patients, including let-7 and miR-26 families. The pattern of reductions was dependent on the disease phenotypic expression and progression rate, making them potentially useful for diagnostic purposes [266]. In turn, upregulation of miR-223-3p, miR-326, and miR-338-3p observed in tissue bank neuromuscular junction samples of ALS patients may disturb HIF-1 and brain-derived neurotrophic factor signaling [267]. Disruption of the intraneuronal localization of RNAi machinery (leading to deregulated axonal protein synthesis) has also been noted as an important aspect of ALS pathology [268]. Moreover, degenerating/dying neurons release miRNA-218 which leads to changes in astrocyte phenotype such as reduced expression of excitatory amino acid transporter 2 or peroxisome proliferator-activated receptor gamma coactivator 1α and to astrogliosis which likely contributes to the neuron loss [269].

Concluding Remarks

Neurodegenerative disorders belong to the most widespread, devastating, and uncontrollable diseases. Alzheimer’s, Parkinson’s, and Huntington’s diseases and amyotrophic lateral sclerosis are, like physiological aging, increasingly associated with pronounced disturbances in the metabolism of bioactive sphingolipids (generally tending to augment the pro-apoptotic ceramide signaling at the expense of survival signals mediated by S1P). However, recent findings suggest a more complex picture, creating the need for refinement of current knowledge on of the roles of S1P and ceramides in the various cell death modes. The early appearance of sphingolipid alterations suggests their engagement in upstream steps of disease development. These observations raise hopes for identification of therapeutic targets that would allow reaching beyond the current symptomatic treatments. They also should help in the identification of highly usable biomarkers for the still elusive goal of early diagnosis.

Besides cell survival/death signaling, the roles of sphingolipids are more obscure. Their significance in the metabolism of AβPP/Aβ and ASN, with both proteins’ physiological roles still unclear, needs extensive insights before conclusions can be drawn. Similar is the significance of sphingolipids’ links with secretion mechanisms which can affect the spread of aggregating proteins, death/survival signals, or metabolic regulators such as noncoding RNAs. The significance of miRNAs for neurodegenerative disorders, although gaining increasing recognition in the field, is still largely uncharacterized.

A final question is that about the availability of therapeutic tools to manipulate the extremely complex network of sphingolipid metabolism. Some of the most basic needs may be met with currently available repurposed drugs such as fingolimod; however, it is highly possible that exploitation of sphingolipids as therapeutic targets (as opposed to their use in diagnosis) may require significant expansion of the current toolset.

Notes

Funding

The work was supported by the National Science Centre (PL) Grant No. 2013/11/N/NZ4/02233 (Chapters 1–4), an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB) and a National Institute of Health (NIH) grant NIA AG038834 and Mossakowski Medical Research Centre Polish Academy of Sciences –T. No. 7 (Chapter 5).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Winblad B, Amouyel P, Andrieu S et al (2016) Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 15:455–532.  https://doi.org/10.1016/S1474-4422(16)00062-4 CrossRefPubMedGoogle Scholar
  2. 2.
    Brunkhorst R, Vutukuri R, Pfeilschifter W (2014) Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci 8:283.  https://doi.org/10.3389/fncel.2014.00283 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gao Y-L, Wang N, Sun F-R et al (2018) Tau in neurodegenerative disease. Ann Transl Med 6:175.  https://doi.org/10.21037/atm.2018.04.23 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jęśko H, Lenkiewicz AM, Adamczyk A (2017) Treatments and compositions targeting α-synuclein: a patent review (2010-2016). Expert Opin Ther Pat 27:427–438.  https://doi.org/10.1080/13543776.2017.1261112 CrossRefPubMedGoogle Scholar
  5. 5.
    de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535.  https://doi.org/10.1016/S1474-4422(06)70471-9 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Aarsland D, Creese B, Politis M et al (2017) Cognitive decline in Parkinson disease. Nat Rev Neurol 13:217–231.  https://doi.org/10.1038/nrneurol.2017.27 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Nakamura S, Fukai E, Miya S et al (2011) Sphingolipid signaling and neuronal function. Chem Phys Lipids 164:S9.  https://doi.org/10.1016/J.CHEMPHYSLIP.2011.05.023 CrossRefGoogle Scholar
  8. 8.
    Jęśko H, Stępień A, Lukiw WJ, Strosznajder RP (2018) The cross-talk between sphingolipids and insulin-like growth factor signaling: significance for aging and neurodegeneration. Mol Neurobiol  https://doi.org/10.1007/s12035-018-1286-3
  9. 9.
    Mencarelli C, Martinez-Martinez P (2013) Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci 70:181–203.  https://doi.org/10.1007/s00018-012-1038-x CrossRefPubMedGoogle Scholar
  10. 10.
    Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510:58–67.  https://doi.org/10.1038/nature13475 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Airola MV, Hannun YA (2013) Sphingolipid metabolism and neutral sphingomyelinases. In: Gulbins E., Petrache I. (eds) Sphingolipids: Basic Science and Drug Development. Handb Exp Pharmacol 215:57–76. Springer, Vienna.  https://doi.org/10.1007/978-3-7091-1368-4_3
  12. 12.
    Motyl J, Strosznajder JB (2018) Sphingosine kinase 1/sphingosine-1-phosphate receptors dependent signalling in neurodegenerative diseases. The promising target for neuroprotection in Parkinson’s disease. Pharmacol Rep 70:1010–1014.  https://doi.org/10.1016/j.pharep.2018.05.002 CrossRefPubMedGoogle Scholar
  13. 13.
    Hagen N, Hans M, Hartmann D et al (2011) Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Cell Death Differ 18:1356–1365.  https://doi.org/10.1038/cdd.2011.7 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rotthier A, Auer-Grumbach M, Janssens K et al (2010) Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am J Hum Genet 87:513–522.  https://doi.org/10.1016/j.ajhg.2010.09.010 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Spassieva SD, Ji X, Liu Y et al (2016) Ectopic expression of ceramide synthase 2 in neurons suppresses neurodegeneration induced by ceramide synthase 1 deficiency. Proc Natl Acad Sci U S A 113:5928–5933.  https://doi.org/10.1073/pnas.1522071113 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhao L, Spassieva SD, Jucius TJ et al (2011) A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation. PLoS Genet 7:e1002063.  https://doi.org/10.1371/journal.pgen.1002063 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Eberle M, Ebel P, Mayer CA et al (2015) Exacerbation of experimental autoimmune encephalomyelitis in ceramide synthase 6 knockout mice is associated with enhanced activation/migration of neutrophils. Immunol Cell Biol 93:825–836.  https://doi.org/10.1038/icb.2015.47 CrossRefPubMedGoogle Scholar
  18. 18.
    McGovern MM, Avetisyan R, Sanson B-J, Lidove O (2017) Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis 12:41.  https://doi.org/10.1186/s13023-017-0572-x CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sikora J, Dworski S, Jones EE et al (2017) Acid ceramidase deficiency in mice results in a broad range of central nervous system abnormalities. Am J Pathol 187:864–883.  https://doi.org/10.1016/j.ajpath.2016.12.005 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang K, Xu R, Schrandt J et al (2015) Alkaline ceramidase 3 deficiency results in Purkinje cell degeneration and cerebellar Ataxia due to dyshomeostasis of sphingolipids in the brain. PLoS Genet 11:e1005591.  https://doi.org/10.1371/journal.pgen.1005591 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lu M-H, Takemoto M, Watanabe K et al (2012) Deficiency of sphingomyelin synthase-1 but not sphingomyelin synthase-2 causes hearing impairments in mice. J Physiol 590:4029–4044.  https://doi.org/10.1113/jphysiol.2012.235846 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang M, Uchiumi O, Ogiso H et al (2017) Stressful learning paradigm precludes manifestation of cognitive ability in sphingomyelin synthase-2 knockout mice. Behav Brain Res 319:25–30.  https://doi.org/10.1016/j.bbr.2016.11.010 CrossRefPubMedGoogle Scholar
  23. 23.
    Kono M, Belyantseva IA, Skoura A et al (2007) Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem 282:10690–10696.  https://doi.org/10.1074/jbc.M700370200 CrossRefPubMedGoogle Scholar
  24. 24.
    MacLennan AJ, Carney PR, Zhu WJ et al (2001) An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 14:203–209CrossRefGoogle Scholar
  25. 25.
    Cutler RG, Thompson KW, Camandola S et al (2014) Sphingolipid metabolism regulates development and lifespan in Caenorhabditis elegans. Mech Ageing Dev 143–144:9–18.  https://doi.org/10.1016/j.mad.2014.11.002 CrossRefPubMedGoogle Scholar
  26. 26.
    Yang Q, Gong Z-J, Zhou Y et al (2010) Role of Drosophila alkaline ceramidase (Dacer) in Drosophila development and longevity. Cell Mol Life Sci 67:1477–1490.  https://doi.org/10.1007/s00018-010-0260-7 CrossRefPubMedGoogle Scholar
  27. 27.
    Jové M, Naudí A, Gambini J et al (2017) A stress-resistant Lipidomic signature confers extreme longevity to humans. J Gerontol A Biol Sci Med Sci 72:30–37.  https://doi.org/10.1093/gerona/glw048 CrossRefPubMedGoogle Scholar
  28. 28.
    Couttas TA, Kain N, Suchowerska AK et al (2016) Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer’s disease. Neurobiol Aging 43:89–100.  https://doi.org/10.1016/j.neurobiolaging.2016.03.027 CrossRefPubMedGoogle Scholar
  29. 29.
    Han XM, Holtzman D, McKeel DW et al (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J Neurochem 82:809–818CrossRefGoogle Scholar
  30. 30.
    Giussani P, Tringali C, Riboni L et al (2014) Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int J Mol Sci 15:4356–4392.  https://doi.org/10.3390/ijms15034356 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    O’Sullivan S, Dev KK (2017) Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases. Neuropharmacology 113:597–607.  https://doi.org/10.1016/j.neuropharm.2016.11.006 CrossRefPubMedGoogle Scholar
  32. 32.
    Granado MH, Gangoiti P, Ouro A et al (2009) Ceramide 1-phosphate (C1P) promotes cell migration involvement of a specific C1P receptor. Cell Signal 21:405–412.  https://doi.org/10.1016/j.cellsig.2008.11.003 CrossRefPubMedGoogle Scholar
  33. 33.
    Abdelbaset-Ismail A, Cymer M, Borkowska-Rzeszotek S, et al (2018) Bioactive phospholipids enhance migration and adhesion of human leukemic cells by inhibiting Heme oxygenase 1 (HO-1) and inducible nitric oxygenase synthase (iNOS) in a p38 MAPK-dependent manner. Stem Cell Rev  https://doi.org/10.1007/s12015-018-9853-6
  34. 34.
    Nagahashi M, Takabe K, Terracina KP et al (2014) Sphingosine-1-phosphate transporters as targets for cancer therapy. Biomed Res Int 2014:1–7.  https://doi.org/10.1155/2014/651727 CrossRefGoogle Scholar
  35. 35.
    Farooqui AA, Ong W-Y, Farooqui T (2010) Lipid mediators in the nucleus: their potential contribution to Alzheimer’s disease. Biochim Biophys Acta 1801:906–916.  https://doi.org/10.1016/j.bbalip.2010.02.002 CrossRefPubMedGoogle Scholar
  36. 36.
    Rutherford C, Childs S, Ohotski J et al (2013) Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death Dis 4:e927.  https://doi.org/10.1038/cddis.2013.455 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Jazvinšćak Jembrek M, Hof PR, Šimić G (2015) Ceramides in Alzheimer’s disease: key mediators of neuronal apoptosis induced by oxidative stress and Aβ accumulation. Oxidative Med Cell Longev 2015:346783.  https://doi.org/10.1155/2015/346783 CrossRefGoogle Scholar
  38. 38.
    Snook CF, Jones JA, Hannun YA (2006) Sphingolipid-binding proteins. Biochim Biophys Acta 1761:927–946.  https://doi.org/10.1016/j.bbalip.2006.06.004 CrossRefPubMedGoogle Scholar
  39. 39.
    Xu R, Wang K, Mileva I et al (2016) Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response. Oncotarget 7:18440–18457.  https://doi.org/10.18632/oncotarget.7825 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Gómez-Muñoz A, Kong JY, Salh B, Steinbrecher UP (2004) Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J Lipid Res 45:99–105.  https://doi.org/10.1194/jlr.M300158-JLR200 CrossRefPubMedGoogle Scholar
  41. 41.
    Granado MH, Gangoiti P, Ouro A et al (2009) Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages. Biochim Biophys Acta 1791:263–272.  https://doi.org/10.1016/j.bbalip.2009.01.023 CrossRefPubMedGoogle Scholar
  42. 42.
    Rivera I-G, Ordoñez M, Presa N et al (2015) Sphingomyelinase D/ceramide 1-phosphate in cell survival and inflammation. Toxins (Basel) 7:1457–1466.  https://doi.org/10.3390/toxins7051457 CrossRefGoogle Scholar
  43. 43.
    Choi JW, Chun J (2013) Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta - Mol Cell Biol Lipids 1831:20–32.  https://doi.org/10.1016/j.bbalip.2012.07.015 CrossRefGoogle Scholar
  44. 44.
    Couttas TA, Kain N, Tran C et al (2018) Age-dependent changes to sphingolipid balance in the human hippocampus are gender-specific and may sensitize to neurodegeneration. J Alzheimers Dis 63:503–514.  https://doi.org/10.3233/JAD-171054 CrossRefPubMedGoogle Scholar
  45. 45.
    Pyszko JA, Strosznajder JB (2014) The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson’s disease. Folia Neuropathol 52:260–269CrossRefGoogle Scholar
  46. 46.
    Motyl J, Przykaza Ł, Kosson P, Boguszewski P, Strosznajder J (2015) P.5.c.002 sphingosine kinase 1 mediated signalling in Parkinson’s disease animal model. Neuroprotective effect of fingolimod and a D2/D3 dopamine receptor agonist. Eur Neuropsychopharmacol 25:S586–S587.  https://doi.org/10.1016/S0924-977X(15)30824-5 CrossRefGoogle Scholar
  47. 47.
    Czubowicz K, Strosznajder R (2014) Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. Mol Neurobiol 50:26–37.  https://doi.org/10.1007/s12035-013-8606-4 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Huang K, Huang J, Chen C et al (2014) AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose. Cell Signal 26:629–638.  https://doi.org/10.1016/j.cellsig.2013.12.002 CrossRefPubMedGoogle Scholar
  49. 49.
    Wegner M-S, Wanger RA, Oertel S et al (2014) Ceramide synthases CerS4 and CerS5 are upregulated by 17β-estradiol and GPER1 via AP-1 in human breast cancer cells. Biochem Pharmacol 92:577–589.  https://doi.org/10.1016/j.bcp.2014.10.007 CrossRefPubMedGoogle Scholar
  50. 50.
    O’Neill SM, Houck KL, Yun JK et al (2011) AP-1 binding transcriptionally regulates human neutral ceramidase. Arch Biochem Biophys 511:31–39.  https://doi.org/10.1016/j.abb.2011.04.009 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Manna SK, Sah NK, Aggarwal BB (2000) Protein tyrosine kinase p56lck is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-kappa B, AP-1, JNK, and apoptosis. J Biol Chem 275:13297–13306CrossRefGoogle Scholar
  52. 52.
    Dong Y-F, Guo R-B, Ji J et al (2018) S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NFκB signalling. J Cell Mol Med 22:3159–3166.  https://doi.org/10.1111/jcmm.13596 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Klotz L-O, Sánchez-Ramos C, Prieto-Arroyo I et al (2015) Redox regulation of FOXO transcription factors. Redox Biol 6:51–72.  https://doi.org/10.1016/j.redox.2015.06.019 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Maiese K (2018) Forkhead transcription factors: formulating a FOXO target for cognitive loss. Curr Neurovasc Res 14:415–420.  https://doi.org/10.2174/1567202614666171116102911 CrossRefGoogle Scholar
  55. 55.
    Kogot-Levin A, Saada A (2014) Ceramide and the mitochondrial respiratory chain. Biochimie 100:88–94.  https://doi.org/10.1016/J.BIOCHI.2013.07.027 CrossRefPubMedGoogle Scholar
  56. 56.
    Stoica BA, Movsesyan VA, Knoblach SM, Faden AI (2005) Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins. Mol Cell Neurosci 29:355–371.  https://doi.org/10.1016/j.mcn.2005.02.009 CrossRefPubMedGoogle Scholar
  57. 57.
    Sentelle RD, Senkal CE, Jiang W et al (2012) Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol 8:831–838.  https://doi.org/10.1038/nchembio.1059 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Jiang W, Ogretmen B (2014) Autophagy paradox and ceramide. Biochim Biophys Acta - Mol Cell Biol Lipids 1841:783–792.  https://doi.org/10.1016/j.bbalip.2013.09.005 CrossRefGoogle Scholar
  59. 59.
    Hait NC, Allegood J, Maceyka M et al (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325:1254–1257.  https://doi.org/10.1126/science.1176709 CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Schmitt HM, Schlamp CL, Nickells RW (2018) Targeting HDAC3 activity with RGFP966 protects against retinal ganglion cell nuclear atrophy and apoptosis after optic nerve injury. J Ocul Pharmacol Ther 34:260–273.  https://doi.org/10.1089/jop.2017.0059 CrossRefPubMedGoogle Scholar
  61. 61.
    Jeong M-H, Ko H, Jeon H et al (2016) Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells. Oncotarget 7:56767–56780.  https://doi.org/10.18632/oncotarget.10790 CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Lee S-H, Seo J, Park S-Y et al (2018) Programmed cell death 5 suppresses AKT-mediated cytoprotection of endothelium. Proc Natl Acad Sci 115:201712918.  https://doi.org/10.1073/pnas.1712918115 CrossRefGoogle Scholar
  63. 63.
    Malaplate-Armand C, Florent-Béchard S, Youssef I et al (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 23:178–189.  https://doi.org/10.1016/j.nbd.2006.02.010 CrossRefGoogle Scholar
  64. 64.
    Pchejetski D, Kunduzova O, Dayon A et al (2007) Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100:41–49.  https://doi.org/10.1161/01.RES.0000253900.66640.34 CrossRefPubMedGoogle Scholar
  65. 65.
    Couttas TA, Kain N, Daniels B et al (2014) Loss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis. Acta Neuropathol Commun 2:9.  https://doi.org/10.1186/2051-5960-2-9 CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Czubowicz K, Cieślik M, Pyszko J et al (2015) Sphingosine-1-phosphate and its effect on glucose deprivation/glucose reload stress: from gene expression to neuronal survival. Mol Neurobiol 51:1300–1308.  https://doi.org/10.1007/s12035-014-8807-5 CrossRefPubMedGoogle Scholar
  67. 67.
    Van Brocklyn JR, Williams JB (2012) The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol 163:26–36.  https://doi.org/10.1016/j.cbpb.2012.05.006 CrossRefPubMedGoogle Scholar
  68. 68.
    Chen W, Lu H, Yang J et al (2016) Sphingosine 1-phosphate in metabolic syndrome (review). Int J Mol Med 38:1030–1038.  https://doi.org/10.3892/ijmm.2016.2731 CrossRefPubMedGoogle Scholar
  69. 69.
    Hasegawa Y, Suzuki H, Sozen T et al (2010) Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 41:368–374.  https://doi.org/10.1161/STROKEAHA.109.568899 CrossRefPubMedGoogle Scholar
  70. 70.
    Safarian F, Khallaghi B, Ahmadiani A, Dargahi L (2015) Activation of S1P1 receptor regulates PI3K/Akt/FOXO3a pathway in response to oxidative stress in PC12 cells. J Mol Neurosci 56:177–187.  https://doi.org/10.1007/s12031-014-0478-1 CrossRefPubMedGoogle Scholar
  71. 71.
    Moloney AM, Griffin RJ, Timmons S et al (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224–243.  https://doi.org/10.1016/j.neurobiolaging.2008.04.002 CrossRefPubMedGoogle Scholar
  72. 72.
    Lauzon M-A, Daviau A, Marcos B, Faucheux N (2015) Growth factor treatment to overcome Alzheimer’s dysfunctional signaling. Cell Signal 27:1025–1038.  https://doi.org/10.1016/j.cellsig.2015.02.018 CrossRefPubMedGoogle Scholar
  73. 73.
    Hsu C-K, Lee I-T, Lin C-C et al (2015) Sphingosine-1-phosphate mediates COX-2 expression and PGE2 /IL-6 secretion via c-Src-dependent AP-1 activation. J Cell Physiol 230:702–715.  https://doi.org/10.1002/jcp.24795 CrossRefPubMedGoogle Scholar
  74. 74.
    Alvarez SE, Harikumar KB, Hait NC et al (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465:1084–1088.  https://doi.org/10.1038/nature09128 CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Xia P, Wang L, Moretti PAB et al (2002) Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem 277:7996–8003.  https://doi.org/10.1074/jbc.M111423200 CrossRefPubMedGoogle Scholar
  76. 76.
    Dai Y, Rahmani M, Dent P, Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25:5429–5444.  https://doi.org/10.1128/MCB.25.13.5429-5444.2005 CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Wang Y, Yang R, Gu J et al (2015) Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging 36:188–200.  https://doi.org/10.1016/j.neurobiolaging.2014.07.035 CrossRefPubMedGoogle Scholar
  78. 78.
    Ghasemi R, Dargahi L, Ahmadiani A (2016) Integrated sphingosine-1 phosphate signaling in the central nervous system: from physiological equilibrium to pathological damage. Pharmacol Res 104:156–164.  https://doi.org/10.1016/j.phrs.2015.11.006 CrossRefPubMedGoogle Scholar
  79. 79.
    Vesely PW, Staber PB, Hoefler G, Kenner L (2009) Translational regulation mechanisms of AP-1 proteins. Mutat Res Mutat Res 682:7–12.  https://doi.org/10.1016/j.mrrev.2009.01.001 CrossRefPubMedGoogle Scholar
  80. 80.
    Sawe N, Steinberg G, Zhao H (2008) Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. J Neurosci Res 86:1659–1669.  https://doi.org/10.1002/jnr.21604 CrossRefPubMedGoogle Scholar
  81. 81.
    Subramaniam S, Unsicker K (2010) ERK and cell death: ERK1/2 in neuronal death. FEBS J 277:22–29.  https://doi.org/10.1111/j.1742-4658.2009.07367.x CrossRefPubMedGoogle Scholar
  82. 82.
    Wang L, Cheng B-F, Yang H-J et al (2015) NF-κB protects human neuroblastoma cells from nitric oxide-induced apoptosis through upregulating biglycan. Am J Transl Res 7:1541–1552PubMedPubMedCentralGoogle Scholar
  83. 83.
    Kim A, Nam YJ, Lee CS (2017) Taxifolin reduces the cholesterol oxidation product-induced neuronal apoptosis by suppressing the Akt and NF-κB activation-mediated cell death. Brain Res Bull 134:63–71.  https://doi.org/10.1016/j.brainresbull.2017.07.008 CrossRefPubMedGoogle Scholar
  84. 84.
    Schwartz NU, Linzer RW, Truman J-P et al (2018) Decreased ceramide underlies mitochondrial dysfunction in Charcot-Marie-Tooth 2F. FASEB J 32:1716–1728.  https://doi.org/10.1096/fj.201701067R CrossRefPubMedGoogle Scholar
  85. 85.
    van Blitterswijk WJ, van der Luit AH, Veldman RJ et al (2003) Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J 369:199–211.  https://doi.org/10.1042/BJ20021528 CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Mesicek J, Lee H, Feldman T et al (2010) Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal 22:1300–1307.  https://doi.org/10.1016/j.cellsig.2010.04.006 CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Cruickshanks N, Roberts JL, Bareford MD et al (2015) Differential regulation of autophagy and cell viability by ceramide species. Cancer Biol Ther 16:733–742.  https://doi.org/10.1080/15384047.2015.1026509 CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Ghosh S, Bhattacharyya S, Sirkar M et al (2002) Leishmania donovani suppresses activated protein 1 and NF-kappaB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase. Infect Immun 70:6828–6838CrossRefGoogle Scholar
  89. 89.
    Colombini M (2017) Ceramide channels and mitochondrial outer membrane permeability. J Bioenerg Biomembr 49:57–64.  https://doi.org/10.1007/s10863-016-9646-z CrossRefPubMedGoogle Scholar
  90. 90.
    Liu Z, Li T, Li P et al (2015) The ambiguous relationship of oxidative stress, tau hyperphosphorylation, and autophagy dysfunction in Alzheimer’s disease. Oxidative Med Cell Longev 2015:352723.  https://doi.org/10.1155/2015/352723 CrossRefGoogle Scholar
  91. 91.
    Zhang L, Wang L, Wang R et al (2017) Evaluating the effectiveness of GTM-1, rapamycin, and carbamazepine on autophagy and Alzheimer disease. Med Sci Monit 23:801–808CrossRefGoogle Scholar
  92. 92.
    Šmidák R, Köfeler HC, Hoeger H, Lubec G (2017) Comprehensive identification of age-related lipidome changes in rat amygdala during normal aging. PLoS One 12:e0180675.  https://doi.org/10.1371/journal.pone.0180675 CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Babenko NA, Garkavenko VV, Storozhenko GV, Timofiychuk OA (2016) Role of acid sphingomyelinase in the age-dependent dysregulation of sphingolipids turnover in the tissues of rats. Gen Physiol Biophys 35:195–205.  https://doi.org/10.4149/gpb_2015046 CrossRefPubMedGoogle Scholar
  94. 94.
    Mielke MM, Bandaru VVR, Han D et al (2015) Factors affecting longitudinal trajectories of plasma sphingomyelins: the Baltimore Longitudinal Study of Aging. Aging Cell 14:112–121.  https://doi.org/10.1111/acel.12275 CrossRefPubMedGoogle Scholar
  95. 95.
    Obeid LM, Hannun YA (2003) Ceramide, stress, and a “lag” in aging. Sci Aging Knowl Environ 2003:PE27.  https://doi.org/10.1126/sageke.2003.39.pe27 CrossRefGoogle Scholar
  96. 96.
    Huang X, Withers BR, Dickson RC (2014) Sphingolipids and lifespan regulation. Biochim Biophys Acta - Mol Cell Biol Lipids 1841:657–664.  https://doi.org/10.1016/j.bbalip.2013.08.006 CrossRefGoogle Scholar
  97. 97.
    Jiang JC, Kirchman PA, Allen M, Jazwinski SM (2004) Suppressor analysis points to the subtle role of the LAG1 ceramide synthase gene in determining yeast longevity. Exp Gerontol 39:999–1009.  https://doi.org/10.1016/j.exger.2004.03.026 CrossRefPubMedGoogle Scholar
  98. 98.
    Kim Y, Sun H (2012) ASM-3 acid sphingomyelinase functions as a positive regulator of the DAF-2/AGE-1 signaling pathway and serves as a novel anti-aging target. PLoS One 7:e45890.  https://doi.org/10.1371/journal.pone.0045890 CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Osawa Y, Banno Y, Nagaki M et al (2001) TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J Immunol 167:173–180CrossRefGoogle Scholar
  100. 100.
    Schubert KM, Scheid MP, Duronio V (2000) Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473. J Biol Chem 275:13330–13335CrossRefGoogle Scholar
  101. 101.
    Brown-Borg HM (2015) The somatotropic axis and longevity in mice. Am J Physiol Endocrinol Metab 309:E503–E510.  https://doi.org/10.1152/ajpendo.00262.2015 CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Selman C, Partridge L, Withers DJ (2011) Replication of extended lifespan phenotype in mice with deletion of insulin receptor substrate 1. PLoS One 6:e16144.  https://doi.org/10.1371/journal.pone.0016144 CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Kappeler L, Filho CDM, Dupont J et al (2008) Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol 6:e254.  https://doi.org/10.1371/journal.pbio.0060254 CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Taguchi A, Wartschow LM, White MF (2007) Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317(80):369–372.  https://doi.org/10.1126/science.1142179 CrossRefPubMedGoogle Scholar
  105. 105.
    Bokov AF, Garg N, Ikeno Y et al (2011) Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One 6:e26891.  https://doi.org/10.1371/journal.pone.0026891 CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Deelen J, Uh H-W, Monajemi R et al (2013) Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. Age (Dordr) 35:235–249.  https://doi.org/10.1007/s11357-011-9340-3 CrossRefGoogle Scholar
  107. 107.
    Suh Y, Atzmon G, Cho M-O et al (2008) Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 105:3438–3442.  https://doi.org/10.1073/pnas.0705467105 CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Ceda GP, Dall’Aglio E, Maggio M et al (2005) Clinical implications of the reduced activity of the GH-IGF-I axis in older men. J Endocrinol Investig 28:96–100Google Scholar
  109. 109.
    Okereke O, Kang JH, Ma J et al (2007) Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging 28:135–142.  https://doi.org/10.1016/j.neurobiolaging.2005.10.012 CrossRefPubMedGoogle Scholar
  110. 110.
    Morel GR, León ML, Uriarte M et al (2017) Therapeutic potential of IGF-I on hippocampal neurogenesis and function during aging. Neurogenesis 4:e1259709.  https://doi.org/10.1080/23262133.2016.1259709 CrossRefPubMedGoogle Scholar
  111. 111.
    Pardo J, Abba MC, Lacunza E et al (2018) IGF-I gene therapy in aging rats modulates hippocampal genes relevant to memory function. J Gerontol A Biol Sci Med Sci 73:459–467.  https://doi.org/10.1093/gerona/glx125 CrossRefPubMedGoogle Scholar
  112. 112.
    Bernacchioni C, Cencetti F, Blescia S et al (2012) Sphingosine kinase/sphingosine 1-phosphate axis: a new player for insulin-like growth factor-1-induced myoblast differentiation. Skelet Muscle 2:15.  https://doi.org/10.1186/2044-5040-2-15 CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Marfe G, Di Stefano C, Gambacurta A et al (2011) Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol 39:653–665.e6.  https://doi.org/10.1016/j.exphem.2011.02.013 CrossRefPubMedGoogle Scholar
  114. 114.
    Till KJ, Pettitt AR, Slupsky JR (2015) Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. J Immunol 194:2439–2446.  https://doi.org/10.4049/jimmunol.1402304 CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Giussani P, Brioschi L, Bassi R et al (2009) Phosphatidylinositol 3-kinase/AKT pathway regulates the endoplasmic reticulum to golgi traffic of ceramide in glioma cells: a link between lipid signaling pathways involved in the control of cell survival. J Biol Chem 284:5088–5096.  https://doi.org/10.1074/jbc.M808934200 CrossRefPubMedGoogle Scholar
  116. 116.
    Banno Y, Takuwa Y, Akao Y et al (2001) Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. J Biol Chem 276:35622–35628.  https://doi.org/10.1074/jbc.M105673200 CrossRefPubMedGoogle Scholar
  117. 117.
    Davaille J, Li L, Mallat A, Lotersztajn S (2002) Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem 277:37323–37330.  https://doi.org/10.1074/jbc.M202798200 CrossRefPubMedGoogle Scholar
  118. 118.
    Cui H, Okamoto Y, Yoshioka K et al (2013) Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice. J Allergy Clin Immunol 132:1205–1214.e9.  https://doi.org/10.1016/j.jaci.2013.07.026 CrossRefPubMedGoogle Scholar
  119. 119.
    Salinas M, López-Valdaliso R, Martín D et al (2000) Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 15:156–169.  https://doi.org/10.1006/mcne.1999.0813 CrossRefPubMedGoogle Scholar
  120. 120.
    Qin J, Berdyshev E, Poirer C et al (2012) Neutral sphingomyelinase 2 deficiency increases hyaluronan synthesis by up-regulation of Hyaluronan synthase 2 through decreased ceramide production and activation of Akt. J Biol Chem 287:13620–13632.  https://doi.org/10.1074/jbc.M111.304857 CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Gómez-Muñoz A, Kong JY, Parhar K et al (2005) Ceramide-1-phosphate promotes cell survival through activation of the phosphatidylinositol 3-kinase/protein kinase B pathway. FEBS Lett 579:3744–3750.  https://doi.org/10.1016/j.febslet.2005.05.067 CrossRefPubMedGoogle Scholar
  122. 122.
    Gangoiti P, Granado MH, Wang SW et al (2008) Ceramide 1-phosphate stimulates macrophage proliferation through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways. Cell Signal 20:726–736.  https://doi.org/10.1016/j.cellsig.2007.12.008 CrossRefPubMedGoogle Scholar
  123. 123.
    Huwiler A, Kotelevets N, Xin C et al (2011) Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br J Pharmacol 162:532–543.  https://doi.org/10.1111/j.1476-5381.2010.01053.x CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Dbaibo GS, Pushkareva MY, Rachid RA et al (1998) p53-dependent ceramide response to genotoxic stress. J Clin Invest 102:329–339.  https://doi.org/10.1172/JCI1180 CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Cutler RG, Pedersen WA, Camandola S et al (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 52:448–457.  https://doi.org/10.1002/ana.10312 CrossRefPubMedGoogle Scholar
  126. 126.
    Liu B, Hannun YA (1997) Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272:16281–16287CrossRefGoogle Scholar
  127. 127.
    Kosicek M, Zetterberg H, Andreasen N et al (2012) Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer’s disease. Neurosci Lett 516:302–305.  https://doi.org/10.1016/j.neulet.2012.04.019 CrossRefPubMedGoogle Scholar
  128. 128.
    Olsen ASB, Færgeman NJ (2017) Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol 7:170069.  https://doi.org/10.1098/rsob.170069 CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Ohno-Iwashita Y, Shimada Y, Hayashi M, Inomata M (2010) Plasma membrane microdomains in aging and disease. Geriatr Gerontol Int 10(Suppl 1):S41–S52.  https://doi.org/10.1111/j.1447-0594.2010.00600.x CrossRefPubMedGoogle Scholar
  130. 130.
    Badawy SMM, Okada T, Kajimoto T et al (2018) Extracellular α-synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G-protein signaling. J Biol Chem 293:8208–8216.  https://doi.org/10.1074/jbc.RA118.001986 CrossRefPubMedGoogle Scholar
  131. 131.
    Grimm MOW, Grösgen S, Rothhaar TL et al (2011) Intracellular APP domain regulates serine-palmitoyl-CoA transferase expression and is affected in Alzheimer’s disease. Int J Alzheimers Dis 2011:695413.  https://doi.org/10.4061/2011/695413 CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Kang MS, Baek S-H, Chun YS et al (2013) Modulation of lipid kinase PI4KIIα activity and lipid raft association of presenilin 1 underlies γ-secretase inhibition by ginsenoside (20S)-Rg3. J Biol Chem 288:20868–20882.  https://doi.org/10.1074/jbc.M112.445734 CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Amaro M, Šachl R, Aydogan G et al (2016) GM1 ganglioside inhibits β-amyloid oligomerization induced by sphingomyelin. Angew Chem Int Ed Engl 55:9411–9415.  https://doi.org/10.1002/anie.201603178 CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Rondelli V, Brocca P, Motta S et al (2016) Amyloid-β peptides in interaction with raft-mime model membranes: a neutron reflectivity insight. Sci Rep 6:20997.  https://doi.org/10.1038/srep20997 CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Peters I, Igbavboa U, Schütt T et al (2009) The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta 1788:964–972.  https://doi.org/10.1016/j.bbamem.2009.01.012 CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Sawamura N, Ko M, Yu W et al (2004) Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem 279:11984–11991.  https://doi.org/10.1074/jbc.M309832200 CrossRefPubMedGoogle Scholar
  137. 137.
    Puglielli L, Ellis BC, Saunders AJ, Kovacs DM (2003) Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278:19777–19783.  https://doi.org/10.1074/jbc.M300466200 CrossRefPubMedGoogle Scholar
  138. 138.
    Takasugi N, Sasaki T, Shinohara M et al (2015) Synthetic ceramide analogues increase amyloid-β 42 production by modulating γ-secretase activity. Biochem Biophys Res Commun 457:194–199.  https://doi.org/10.1016/j.bbrc.2014.12.087 CrossRefPubMedGoogle Scholar
  139. 139.
    Asle-Rousta M, Kolahdooz Z, Oryan S et al (2013) FTY720 (fingolimod) attenuates beta-amyloid peptide (Aβ42)-induced impairment of spatial learning and memory in rats. J Mol Neurosci 50:524–532.  https://doi.org/10.1007/s12031-013-9979-6 CrossRefPubMedGoogle Scholar
  140. 140.
    Joshi P, Gabrielli M, Ponzoni L et al (2017) Fingolimod limits acute Aβ neurotoxicity and promotes synaptic versus extrasynaptic NMDA receptor functionality in hippocampal neurons. Sci Rep 7:41734.  https://doi.org/10.1038/srep41734 CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Takasugi N, Sasaki T, Ebinuma I et al (2013) FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons. PLoS One 8:e64050.  https://doi.org/10.1371/journal.pone.0064050 CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Takasugi N, Sasaki T, Suzuki K et al (2011) BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 31:6850–6857.  https://doi.org/10.1523/JNEUROSCI.6467-10.2011 CrossRefPubMedPubMedCentralGoogle Scholar
  143. 143.
    Dominguez G, Maddelein M-L, Pucelle M et al (2018) Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer’s disease brain. Acta Neuropathol Commun 6:25.  https://doi.org/10.1186/s40478-018-0527-z CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Ceccom J, Loukh N, Lauwers-Cances V et al (2014) Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease. Acta Neuropathol Commun 2:12.  https://doi.org/10.1186/2051-5960-2-12 CrossRefPubMedPubMedCentralGoogle Scholar
  145. 145.
    Karaca I, Tamboli IY, Glebov K et al (2014) Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. J Biol Chem 289:16761–16772.  https://doi.org/10.1074/jbc.M113.535500 CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Jesko H, Okada T, Strosznajder RP, Nakamura S (2014) Sphingosine kinases modulate the secretion of amyloid β precursor protein from SH-SY5Y neuroblastoma cells: the role of α-synuclein. Folia Neuropathol 52:70–78CrossRefGoogle Scholar
  147. 147.
    Jęśko H, Wencel PL, Lukiw WJ, Strosznajder RP (2018) Modulatory effects of fingolimod (FTY720) on the expression of sphingolipid metabolism-related genes in an animal model of Alzheimer’s disease. Mol Neurobiol  https://doi.org/10.1007/s12035-018-1040-x
  148. 148.
    Cutler RG, Kelly J, Storie K et al (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A 101:2070–2075.  https://doi.org/10.1073/pnas.0305799101 CrossRefPubMedPubMedCentralGoogle Scholar
  149. 149.
    Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res 32:845–856.  https://doi.org/10.1007/s11064-007-9297-x CrossRefPubMedGoogle Scholar
  150. 150.
    He X, Huang Y, Li B et al (2010) Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging 31:398–408.  https://doi.org/10.1016/j.neurobiolaging.2008.05.010 CrossRefGoogle Scholar
  151. 151.
    Bandaru VVR, Troncoso J, Wheeler D et al (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiol Aging 30:591–599.  https://doi.org/10.1016/j.neurobiolaging.2007.07.024 CrossRefPubMedGoogle Scholar
  152. 152.
    Lee J-T, Xu J, Lee J-M et al (2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164:123–131.  https://doi.org/10.1083/jcb.200307017 CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Jana A, Pahan K (2004) Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer’s disease J Biol Chem 279:51451–51459.  https://doi.org/10.1074/jbc.M404635200 CrossRefPubMedGoogle Scholar
  154. 154.
    Gomez-Brouchet A, Pchejetski D, Brizuela L et al (2007) Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol Pharmacol 72:341–349.  https://doi.org/10.1124/mol.106.033738 CrossRefPubMedGoogle Scholar
  155. 155.
    Ayasolla K, Khan M, Singh AK, Singh I (2004) Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med 37:325–338.  https://doi.org/10.1016/j.freeradbiomed.2004.04.007 CrossRefPubMedGoogle Scholar
  156. 156.
    Zeng C, Lee JT, Chen H et al (2005) Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem 94:703–712.  https://doi.org/10.1111/j.1471-4159.2005.03217.x CrossRefPubMedGoogle Scholar
  157. 157.
    Martinez TN, Chen X, Bandyopadhyay S et al (2012) Ceramide sphingolipid signaling mediates tumor necrosis factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Mol Neurodegener 7:45.  https://doi.org/10.1186/1750-1326-7-45 CrossRefPubMedPubMedCentralGoogle Scholar
  158. 158.
    Alessenko AV, Bugrova AE, Dudnik LB (2004) Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer’s disease. Biochem Soc Trans 32:144–146.  https://doi.org/10.1000/182 CrossRefPubMedGoogle Scholar
  159. 159.
    Grimm MOW, Grimm HS, Pätzold AJ et al (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat Cell Biol 7:1118–1123.  https://doi.org/10.1038/ncb1313 CrossRefPubMedGoogle Scholar
  160. 160.
    Dinkins MB, Enasko J, Hernandez C et al (2016) Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse. J Neurosci 36:8653–8667.  https://doi.org/10.1523/JNEUROSCI.1429-16.2016 CrossRefPubMedPubMedCentralGoogle Scholar
  161. 161.
    Geekiyanage H, Upadhye A, Chan C (2013) Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer’s disease. Neurobiol Aging 34:2037–2051.  https://doi.org/10.1016/j.neurobiolaging.2013.02.001 CrossRefPubMedPubMedCentralGoogle Scholar
  162. 162.
    Panchal M, Gaudin M, Lazar AN et al (2014) Ceramides and sphingomyelinases in senile plaques. Neurobiol Dis 65:193–201.  https://doi.org/10.1016/j.nbd.2014.01.010 CrossRefPubMedGoogle Scholar
  163. 163.
    Gassowska M, Cieslik M, Wilkaniec A, Strosznajder JB (2014) Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells. Neurochem Res 39:645–652.  https://doi.org/10.1007/s11064-014-1240-3 CrossRefPubMedPubMedCentralGoogle Scholar
  164. 164.
    Kuhle J, Disanto G, Lorscheider J et al (2015) Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 84:1639–1643.  https://doi.org/10.1212/WNL.0000000000001491 CrossRefPubMedPubMedCentralGoogle Scholar
  165. 165.
    Xia P, Gamble JR, Rye KA et al (1998) Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A 95:14196–14201CrossRefGoogle Scholar
  166. 166.
    Kaneider NC, Lindner J, Feistritzer C et al (2004) The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J 18:1309–1311.  https://doi.org/10.1096/fj.03-1050fje CrossRefPubMedGoogle Scholar
  167. 167.
    Dinkins MB, Dasgupta S, Wang G et al (2015) The 5XFAD mouse model of Alzheimer’s disease exhibits an age-dependent increase in anti-ceramide IgG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden. J Alzheimers Dis 46:55–61.  https://doi.org/10.3233/JAD-150088 CrossRefPubMedPubMedCentralGoogle Scholar
  168. 168.
    Liu C-C, Kanekiyo T, Xu H et al (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118.  https://doi.org/10.1038/nrneurol.2012.263 CrossRefPubMedPubMedCentralGoogle Scholar
  169. 169.
    Kurano M, Tsukamoto K, Hara M et al (2015) LDL receptor and ApoE are involved in the clearance of ApoM-associated sphingosine 1-phosphate. J Biol Chem 290:2477–2488.  https://doi.org/10.1074/jbc.M114.596445 CrossRefPubMedGoogle Scholar
  170. 170.
    Han X (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer’s disease. Biochim Biophys Acta 1801:774–783.  https://doi.org/10.1016/j.bbalip.2010.01.010 CrossRefPubMedPubMedCentralGoogle Scholar
  171. 171.
    Gizaw ST, Ohashi T, Tanaka M et al (2016) Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer’s disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. Biochim Biophys Acta 1860:1716–1727.  https://doi.org/10.1016/j.bbagen.2016.03.009 CrossRefPubMedGoogle Scholar
  172. 172.
    Mielke MM, Lyketsos CG (2010) Alterations of the sphingolipid pathway in Alzheimer’s disease: new biomarkers and treatment targets? NeuroMolecular Med 12:331–340.  https://doi.org/10.1007/s12017-010-8121-y CrossRefPubMedPubMedCentralGoogle Scholar
  173. 173.
    Yuyama K, Mitsutake S, Igarashi Y (2014) Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer’s disease. Biochim Biophys Acta 1841:793–798.  https://doi.org/10.1016/j.bbalip.2013.08.002 CrossRefPubMedGoogle Scholar
  174. 174.
    Wang G, Dinkins M, He Q et al (2012) Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). J Biol Chem 287:21384–21395.  https://doi.org/10.1074/jbc.M112.340513 CrossRefPubMedPubMedCentralGoogle Scholar
  175. 175.
    Sharples RA, Vella LJ, Nisbet RM et al (2008) Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J 22:1469–1478.  https://doi.org/10.1096/fj.07-9357.com CrossRefPubMedGoogle Scholar
  176. 176.
    Rajendran L, Honsho M, Zahn TR et al (2006) Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci 103:11172–11177.  https://doi.org/10.1073/pnas.0603838103 CrossRefPubMedGoogle Scholar
  177. 177.
    Dinkins MB, Wang G, Bieberich E (2017) Sphingolipid-enriched extracellular vesicles and Alzheimer’s disease: a decade of research. J Alzheimers Dis 60:757–768.  https://doi.org/10.3233/JAD-160567 CrossRefPubMedPubMedCentralGoogle Scholar
  178. 178.
    Yuyama K, Sun H, Mitsutake S, Igarashi Y (2012) Sphingolipid-modulated exosome secretion promotes clearance of amyloid-β by microglia. J Biol Chem 287:10977–10989.  https://doi.org/10.1074/jbc.M111.324616 CrossRefPubMedPubMedCentralGoogle Scholar
  179. 179.
    Yuyama K, Igarashi Y (2017) Exosomes as carriers of Alzheimer’s amyloid-ß. Front Neurosci 11(229).  https://doi.org/10.3389/fnins.2017.00229
  180. 180.
    Ngolab J, Trinh I, Rockenstein E et al (2017) Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology. Acta Neuropathol Commun 5:46.  https://doi.org/10.1186/s40478-017-0445-5 CrossRefPubMedPubMedCentralGoogle Scholar
  181. 181.
    Wang Y, Balaji V, Kaniyappan S et al (2017) The release and trans-synaptic transmission of tau via exosomes. Mol Neurodegener 12:5.  https://doi.org/10.1186/s13024-016-0143-y CrossRefPubMedPubMedCentralGoogle Scholar
  182. 182.
    Kajimoto T, Mohamed NNI, Badawy SMM et al (2018) Involvement of Gβγ subunits of Gi protein coupled with S1P receptor on multivesicular endosomes in F-actin formation and cargo sorting into exosomes. J Biol Chem 293:245–253.  https://doi.org/10.1074/jbc.M117.808733 CrossRefPubMedGoogle Scholar
  183. 183.
    Dinkins MB, Dasgupta S, Wang G et al (2014) Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol Aging 35:1792–1800.  https://doi.org/10.1016/j.neurobiolaging.2014.02.012 CrossRefPubMedPubMedCentralGoogle Scholar
  184. 184.
    Broe M, Shepherd CE, Mann DMA et al (2005) Insoluble alpha-synuclein in Alzheimer’s disease without Lewy body formation. Neurotox Res 7:69–76CrossRefGoogle Scholar
  185. 185.
    Emmanouilidou E, Vekrellis K (2016) Exocytosis and spreading of normal and aberrant α-synuclein. Brain Pathol 26:398–403.  https://doi.org/10.1111/bpa.12373 CrossRefPubMedGoogle Scholar
  186. 186.
    Christensen DP, Ejlerskov P, Rasmussen I, Vilhardt F (2016) Reciprocal signals between microglia and neurons regulate α-synuclein secretion by exophagy through a neuronal cJUN-N-terminal kinase-signaling axis. J Neuroinflammation 13:59.  https://doi.org/10.1186/s12974-016-0519-5 CrossRefPubMedPubMedCentralGoogle Scholar
  187. 187.
    Paillusson S, Clairembault T, Biraud M et al (2013) Activity-dependent secretion of alpha-synuclein by enteric neurons. J Neurochem 125:512–517.  https://doi.org/10.1111/jnc.12131 CrossRefPubMedGoogle Scholar
  188. 188.
    Ejlerskov P, Rasmussen I, Nielsen TT et al (2013) Tubulin polymerization-promoting protein (TPPP/p25α) promotes unconventional secretion of α-synuclein through exophagy by impairing autophagosome-lysosome fusion. J Biol Chem 288:17313–17335.  https://doi.org/10.1074/jbc.M112.401174 CrossRefPubMedPubMedCentralGoogle Scholar
  189. 189.
    Hasegawa T, Konno M, Baba T et al (2011) The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein. PLoS One 6:e29460.  https://doi.org/10.1371/journal.pone.0029460 CrossRefPubMedPubMedCentralGoogle Scholar
  190. 190.
    Papadopoulos VE, Nikolopoulou G, Antoniadou I et al (2018) Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson’s disease. Hum Mol Genet 27:1696–1710.  https://doi.org/10.1093/hmg/ddy075 CrossRefPubMedGoogle Scholar
  191. 191.
    Zhang S, Eitan E, Wu T-Y, Mattson MP (2018) Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol Aging 61:52–65.  https://doi.org/10.1016/j.neurobiolaging.2017.09.016 CrossRefPubMedGoogle Scholar
  192. 192.
    Abbott SK, Li H, Muñoz SS et al (2014) Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov Disord 29:518–526CrossRefGoogle Scholar
  193. 193.
    Sivasubramanian M, Kanagaraj N, Dheen ST, Tay SSW (2015) Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson’s disease and in MPP+-treated MN9D cells in vitro. Neuroscience 290:636–648.  https://doi.org/10.1016/j.neuroscience.2015.01.032 CrossRefPubMedGoogle Scholar
  194. 194.
    Motyl J, Przykaza Ł, Boguszewski PM, Kosson P, Strosznajder JB (2018) Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology 135:139–150.  https://doi.org/10.1016/j.neuropharm.2018.02.023
  195. 195.
    Ferrazza R, Cogo S, Melrose H et al (2016) LRRK2 deficiency impacts ceramide metabolism in brain. Biochem Biophys Res Commun 478:1141–1146.  https://doi.org/10.1016/j.bbrc.2016.08.082 CrossRefPubMedGoogle Scholar
  196. 196.
    Bras J, Singleton A, Cookson MR, Hardy J (2008) Emerging pathways in genetic Parkinson’s disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 275:5767–5773.  https://doi.org/10.1111/j.1742-4658.2008.06709.x CrossRefPubMedPubMedCentralGoogle Scholar
  197. 197.
    Brodowicz J, Przegaliński E, Müller CP, Filip M (2018) Ceramide and its related neurochemical networks as targets for some brain disorder therapies. Neurotox Res 33:474–484.  https://doi.org/10.1007/s12640-017-9798-6 CrossRefPubMedGoogle Scholar
  198. 198.
    Mielke MM, Maetzler W, Haughey NJ et al (2013) Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study. PLoS One 8:e73094.  https://doi.org/10.1371/journal.pone.0073094 CrossRefPubMedPubMedCentralGoogle Scholar
  199. 199.
    Xing Y, Tang Y, Zhao L et al (2016) Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson’s disease dementia. J Neurol Sci 370:82–87.  https://doi.org/10.1016/j.jns.2016.09.028 CrossRefPubMedGoogle Scholar
  200. 200.
    Mao C, Yang J, Wang H et al (2017) SMPD1 variants in Chinese Han patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord 34:59–61.  https://doi.org/10.1016/j.parkreldis.2016.10.014 CrossRefPubMedGoogle Scholar
  201. 201.
    Gan-Or Z, Orr-Urtreger A, Alcalay RN et al (2015) The emerging role of SMPD1 mutations in Parkinson’s disease: implications for future studies. Parkinsonism Relat Disord 21:1294–1295.  https://doi.org/10.1016/j.parkreldis.2015.08.018 CrossRefPubMedGoogle Scholar
  202. 202.
    Dagan E, Schlesinger I, Ayoub M et al (2015) The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat Disord 21:1067–1071.  https://doi.org/10.1016/j.parkreldis.2015.06.016 CrossRefPubMedGoogle Scholar
  203. 203.
    Foo J-N, Liany H, Bei J-X et al (2013) Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson’s disease. Neurobiol Aging 34:2890.e13–2890.e15.  https://doi.org/10.1016/j.neurobiolaging.2013.06.010 CrossRefGoogle Scholar
  204. 204.
    Deng S, Deng X, Song Z et al (2016) Systematic genetic analysis of the SMPD1 gene in Chinese patients with Parkinson’s disease. Mol Neurobiol 53:5025–5029.  https://doi.org/10.1007/s12035-015-9426-5 CrossRefPubMedGoogle Scholar
  205. 205.
    Pyszko J, Strosznajder JB (2014) Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-Phenylpyridinium (MPP+) in human dopaminergic neuronal cells. Mol Neurobiol 50:38–48.  https://doi.org/10.1007/s12035-013-8622-4 CrossRefPubMedGoogle Scholar
  206. 206.
    Mitroi DN, Karunakaran I, Gräler M et al (2017) SGPL1 (sphingosine phosphate lyase 1) modulates neuronal autophagy via phosphatidylethanolamine production. Autophagy 13:885–899.  https://doi.org/10.1080/15548627.2017.1291471 CrossRefPubMedPubMedCentralGoogle Scholar
  207. 207.
    Ren M, Han M, Wei X et al (2017) FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse parkinsonian models. Neurochem Res 42:686–696.  https://doi.org/10.1007/s11064-016-2125-4 CrossRefPubMedGoogle Scholar
  208. 208.
    Zhao P, Yang X, Yang L et al (2017) Neuroprotective effects of fingolimod in mouse models of Parkinson’s disease. FASEB J 31:172–179.  https://doi.org/10.1096/fj.201600751R CrossRefPubMedGoogle Scholar
  209. 209.
    Komnig D, Dagli CT, Habib P, et al (2018) Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson disease and does not lead to a sustainable increase of brain BDNF. J Neurochem  https://doi.org/10.1111/jnc.14575
  210. 210.
    Kim WS, Halliday GM (2012) Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression. J Parkinsons Dis 2:41–46.  https://doi.org/10.3233/JPD-2012-11059 CrossRefPubMedGoogle Scholar
  211. 211.
    Bienias K, Fiedorowicz A, Sadowska A et al (2016) Regulation of sphingomyelin metabolism. Pharmacol Rep 68:570–581.  https://doi.org/10.1016/j.pharep.2015.12.008 CrossRefPubMedGoogle Scholar
  212. 212.
    Vidal-Martínez G, Vargas-Medrano J, Gil-Tommee C et al (2016) FTY720/fingolimod reduces synucleinopathy and improves gut motility in A53T mice: contributions of pro-brain-derived neurotrophic factor (PRO-BDNF) and mature BDNF. J Biol Chem 291:20811–20821.  https://doi.org/10.1074/jbc.M116.744029 CrossRefPubMedPubMedCentralGoogle Scholar
  213. 213.
    Sato S, Li Y, Hattori N (2017) Lysosomal defects in ATP13A2 and GBA associated familial Parkinson’s disease. J Neural Transm 124:1395–1400.  https://doi.org/10.1007/s00702-017-1779-7 CrossRefPubMedGoogle Scholar
  214. 214.
    Pchelina S, Emelyanov A, Baydakova G et al (2017) Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease. Neurosci Lett 636:70–76.  https://doi.org/10.1016/j.neulet.2016.10.039 CrossRefPubMedGoogle Scholar
  215. 215.
    Jin H, Chen J, Li K et al (2018) A novel p.L216I mutation in the glucocerebrosidase gene is associated with Parkinson’s disease in Han Chinese patients. Neurosci Lett 674:66–69.  https://doi.org/10.1016/j.neulet.2018.03.017 CrossRefPubMedGoogle Scholar
  216. 216.
    Arkadir D, Dinur T, Mullin S et al (2018) Trio approach reveals higher risk of PD in carriers of severe vs. mild GBA mutations. Blood Cells Mol Dis 68:115–116.  https://doi.org/10.1016/j.bcmd.2016.11.007 CrossRefPubMedGoogle Scholar
  217. 217.
    Jesús S, Huertas I, Bernal-Bernal I et al (2016) GBA variants influence motor and non-motor features of Parkinson’s disease. PLoS One 11:e0167749.  https://doi.org/10.1371/journal.pone.0167749 CrossRefPubMedPubMedCentralGoogle Scholar
  218. 218.
    Swan M, Doan N, Ortega RA et al (2016) Neuropsychiatric characteristics of GBA-associated Parkinson disease. J Neurol Sci 370:63–69.  https://doi.org/10.1016/j.jns.2016.08.059 CrossRefPubMedPubMedCentralGoogle Scholar
  219. 219.
    Parnetti L, Paciotti S, Eusebi P et al (2017) Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson’s disease patients. Mov Disord 32:1423–1431.  https://doi.org/10.1002/mds.27136 CrossRefPubMedGoogle Scholar
  220. 220.
    Lunde KA, Chung J, Dalen I et al (2018) Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson’s disease. Alzheimers Dement 14:1293–1301.  https://doi.org/10.1016/j.jalz.2018.04.006 CrossRefPubMedGoogle Scholar
  221. 221.
    Taguchi YV, Liu J, Ruan J et al (2017) Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson’s disease. J Neurosci 37:9617–9631.  https://doi.org/10.1523/JNEUROSCI.1525-17.2017 CrossRefPubMedPubMedCentralGoogle Scholar
  222. 222.
    Guedes LC, Chan RB, Gomes MA et al (2017) Serum lipid alterations in GBA-associated Parkinson’s disease. Parkinsonism Relat Disord 44:58–65.  https://doi.org/10.1016/j.parkreldis.2017.08.026 CrossRefPubMedGoogle Scholar
  223. 223.
    Mazzulli JR, Xu Y-H, Sun Y et al (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52.  https://doi.org/10.1016/j.cell.2011.06.001 CrossRefPubMedPubMedCentralGoogle Scholar
  224. 224.
    Abul Khair SB, Dhanushkodi NR, Ardah MT et al (2018) Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of Parkinson’s disease associated α-synuclein mutant A53T and affects locomotor activity. Front Neurosci 12:81.  https://doi.org/10.3389/fnins.2018.00081 CrossRefPubMedPubMedCentralGoogle Scholar
  225. 225.
    Jung O, Patnaik S, Marugan J et al (2016) Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Rev Proteomics 13:471–479.  https://doi.org/10.1080/14789450.2016.1174583 CrossRefPubMedPubMedCentralGoogle Scholar
  226. 226.
    Di Pardo A, Amico E, Basit A et al (2017) Defective sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease. Sci Rep 7:5280.  https://doi.org/10.1038/s41598-017-05709-y CrossRefPubMedPubMedCentralGoogle Scholar
  227. 227.
    Di Pardo A, Basit A, Armirotti A et al (2017) De novo synthesis of sphingolipids is defective in experimental models of Huntington’s disease. Front Neurosci 11:698.  https://doi.org/10.3389/fnins.2017.00698 CrossRefPubMedPubMedCentralGoogle Scholar
  228. 228.
    Hunter M, Demarais NJ, Faull RLM et al (2018) Subventricular zone lipidomic architecture loss in Huntington’s disease. J Neurochem 146:613–630.  https://doi.org/10.1111/jnc.14468 CrossRefPubMedGoogle Scholar
  229. 229.
    Pirhaji L, Milani P, Leidl M et al (2016) Revealing disease-associated pathways by network integration of untargeted metabolomics. Nat Methods 13:770–776.  https://doi.org/10.1038/nmeth.3940 CrossRefPubMedPubMedCentralGoogle Scholar
  230. 230.
    Pirhaji L, Milani P, Dalin S et al (2017) Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements. Nat Commun 8:623.  https://doi.org/10.1038/s41467-017-00353-6 CrossRefPubMedPubMedCentralGoogle Scholar
  231. 231.
    Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506CrossRefGoogle Scholar
  232. 232.
    Di Pardo A, Amico E, Favellato M et al (2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet 23:2251–2265.  https://doi.org/10.1093/hmg/ddt615 CrossRefPubMedGoogle Scholar
  233. 233.
    Di Pardo A, Castaldo S, Amico E et al (2018) Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington’s disease. Hum Mol Genet 27:2490–2501.  https://doi.org/10.1093/hmg/ddy153 CrossRefPubMedGoogle Scholar
  234. 234.
    Miguez A, García-Díaz Barriga G, Brito V, Straccia M, Giralt A, Ginés S, Canals JM, Alberch J (2015) Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington’s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet 24(17):4958–4970.  https://doi.org/10.1093/hmg/ddv218
  235. 235.
    Di Pardo A, Maglione V (2018) The S1P axis: new exciting route for treating Huntington’s disease. Trends Pharmacol Sci 39:468–480.  https://doi.org/10.1016/j.tips.2018.02.009 CrossRefPubMedGoogle Scholar
  236. 236.
    Henriques A, Croixmarie V, Priestman DA et al (2015) Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet 24:7390–7405.  https://doi.org/10.1093/hmg/ddv439 CrossRefPubMedPubMedCentralGoogle Scholar
  237. 237.
    Dodge JC, Treleaven CM, Pacheco J et al (2015) Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 112:8100–8105.  https://doi.org/10.1073/pnas.1508767112 CrossRefPubMedPubMedCentralGoogle Scholar
  238. 238.
    Henriques A, Croixmarie V, Bouscary A, Mosbach A, Keime C, Boursier-Neyret C, Walter B, Spedding M et al (2018) Sphingolipid metabolism is dysregulated at transcriptomic and metabolic levels in the spinal cord of an animal model of amyotrophic lateral sclerosis. Front Mol Neurosci 10:433.  https://doi.org/10.3389/fnmol.2017.00433
  239. 239.
    Potenza RL, De Simone R, Armida M et al (2016) Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics 13:918–927.  https://doi.org/10.1007/s13311-016-0462-2 CrossRefPubMedPubMedCentralGoogle Scholar
  240. 240.
    Batistela MS, Josviak ND, Sulzbach CD, de Souza RLR (2017) An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer’s and Parkinson’s diseases. Int J Neurosci 127:547–558.  https://doi.org/10.1080/00207454.2016.1209754 CrossRefPubMedGoogle Scholar
  241. 241.
    Nadim WD, Simion V, Benedetti H et al (2017) MicroRNAs in neurocognitive dysfunctions: new molecular targets for pharmacological treatments? Curr Neuropharmacol 15:260–275CrossRefGoogle Scholar
  242. 242.
    Quinlan S, Kenny A, Medina M et al (2017) MicroRNAs in neurodegenerative diseases. Int Rev Cell Mol Biol 334:309–343.  https://doi.org/10.1016/bs.ircmb.2017.04.002 CrossRefPubMedGoogle Scholar
  243. 243.
    Sethi P, Lukiw WJ (2009) Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer’s disease temporal lobe neocortex. Neurosci Lett 459:100–104.  https://doi.org/10.1016/j.neulet.2009.04.052 CrossRefPubMedGoogle Scholar
  244. 244.
    Li YY, Cui JG, Dua P et al (2011) Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells. Neurosci Lett 499:109–113.  https://doi.org/10.1016/j.neulet.2011.05.044 CrossRefPubMedPubMedCentralGoogle Scholar
  245. 245.
    Sarkar S, Jun S, Rellick S et al (2016) Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res 1646:139–151.  https://doi.org/10.1016/j.brainres.2016.05.026 CrossRefPubMedPubMedCentralGoogle Scholar
  246. 246.
    Aloia AL, Abraham AM, Bonder CS et al (2015) Dengue virus-induced inflammation of the endothelium and the potential roles of sphingosine kinase-1 and microRNAs. Mediat Inflamm 2015:509306.  https://doi.org/10.1155/2015/509306 CrossRefGoogle Scholar
  247. 247.
    Gui Y, Liu H, Zhang L et al (2015) Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 6:37043–37053.  https://doi.org/10.18632/oncotarget.6158 CrossRefPubMedPubMedCentralGoogle Scholar
  248. 248.
    Xin Q, Li J, Dang J et al (2015) miR-155 deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1pr1 in Faslpr/lpr mice. J Immunol 194:5437–5445.  https://doi.org/10.4049/jimmunol.1403028 CrossRefPubMedGoogle Scholar
  249. 249.
    Jaber V, Zhao Y, Lukiw WJ (2017) Alterations in micro RNA-messenger RNA (miRNA-mRNA) coupled signaling networks in sporadic Alzheimer’s disease (AD) hippocampal CA1. J Alzheimer’s Dis Park 7:  https://doi.org/10.4172/2161-0460.1000312
  250. 250.
    Pogue AI, Lukiw WJ (2018) Up-regulated pro-inflammatory microRNAs (miRNAs) in Alzheimer’s disease (AD) and age-related macular degeneration (AMD). Cell Mol Neurobiol 38:1021–1031.  https://doi.org/10.1007/s10571-017-0572-3 CrossRefPubMedGoogle Scholar
  251. 251.
    MIR155 Gene—GeneCards | MIR155 RNA Gene. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR155. Accessed 23 Jul 2018
  252. 252.
    Murphy EJ, Schapiro MB, Rapoport SI, Shetty HU (2000) Phospholipid composition and levels are altered in Down syndrome brain. Brain Res 867:9–18CrossRefGoogle Scholar
  253. 253.
    Zhao Y, Jaber V, Percy ME, Lukiw WJ (2017) A microRNA cluster (let-7c, miRNA-99a, miRNA-125b, miRNA-155 and miRNA-802) encoded at chr21q21.1-chr21q21.3 and the phenotypic diversity of Down’s syndrome (DS; trisomy 21). J Nat Sci 3:Google Scholar
  254. 254.
    Charkiewicz K, Blachnio-Zabielska A, Zbucka-Kretowska M et al (2015) Maternal plasma and amniotic fluid sphingolipids profiling in fetal Down syndrome. PLoS One 10:e0127732.  https://doi.org/10.1371/journal.pone.0127732 CrossRefPubMedPubMedCentralGoogle Scholar
  255. 255.
    Zhao Y, Lukiw WJ (2018) Bacteroidetes neurotoxins and inflammatory neurodegeneration. Mol Neurobiol 55:9100–9107.  https://doi.org/10.1007/s12035-018-1015-y CrossRefPubMedGoogle Scholar
  256. 256.
    Heaver SL, Johnson EL, Ley RE (2018) Sphingolipids in host-microbial interactions. Curr Opin Microbiol 43:92–99.  https://doi.org/10.1016/j.mib.2017.12.011 CrossRefPubMedGoogle Scholar
  257. 257.
    Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9:139–150.  https://doi.org/10.1038/nrm2329 CrossRefPubMedGoogle Scholar
  258. 258.
    Packer AN, Xing Y, Harper SQ et al (2008) The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington’s disease. J Neurosci 28:14341–14346.  https://doi.org/10.1523/JNEUROSCI.2390-08.2008 CrossRefPubMedPubMedCentralGoogle Scholar
  259. 259.
    Díez-Planelles C, Sánchez-Lozano P, Crespo MC et al (2016) Circulating microRNAs in Huntington’s disease: emerging mediators in metabolic impairment. Pharmacol Res 108:102–110.  https://doi.org/10.1016/j.phrs.2016.05.005 CrossRefPubMedGoogle Scholar
  260. 260.
    Das E, Jana NR, Bhattacharyya NP (2015) Delayed cell cycle progression in STHdh(Q111)/Hdh(Q111) cells, a cell model for Huntington’s disease mediated by microRNA-19a, microRNA-146a and microRNA-432. MicroRNA (Shariqah, United Arab Emirates) 4:86–100Google Scholar
  261. 261.
    Reynolds RH, Petersen MH, Willert CW et al (2018) Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington’s disease model. Mol Cell Neurosci 88:118–129.  https://doi.org/10.1016/j.mcn.2017.12.009 CrossRefPubMedGoogle Scholar
  262. 262.
    Langfelder P, Gao F, Wang N et al (2018) MicroRNA signatures of endogenous huntingtin CAG repeat expansion in mice. PLoS One 13:e0190550.  https://doi.org/10.1371/journal.pone.0190550 CrossRefPubMedPubMedCentralGoogle Scholar
  263. 263.
    Hoss AG, Lagomarsino VN, Frank S et al (2015) Study of plasma-derived miRNAs mimic differences in Huntington’s disease brain. Mov Disord 30:1961–1964.  https://doi.org/10.1002/mds.26457 CrossRefPubMedPubMedCentralGoogle Scholar
  264. 264.
    Reed ER, Latourelle JC, Bockholt JH et al (2018) MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology 90:e264–e272.  https://doi.org/10.1212/WNL.0000000000004844 CrossRefPubMedPubMedCentralGoogle Scholar
  265. 265.
    Di Pietro L, Lattanzi W, Bernardini C (2018) Skeletal muscle microRNAs as key players in the pathogenesis of amyotrophic lateral sclerosis. Int J Mol Sci 19:1534.  https://doi.org/10.3390/ijms19051534 CrossRefPubMedCentralGoogle Scholar
  266. 266.
    Liguori M, Nuzziello N, Introna A et al (2018) Dysregulation of MicroRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front Mol Neurosci 11:288.  https://doi.org/10.3389/fnmol.2018.00288 CrossRefPubMedPubMedCentralGoogle Scholar
  267. 267.
    De Felice B, Manfellotto F, Fiorentino G et al (2018) Wide-ranging analysis of microRNA profiles in sporadic amyotrophic lateral sclerosis using next-generation sequencing. Front Genet 9:310.  https://doi.org/10.3389/fgene.2018.00310 CrossRefPubMedPubMedCentralGoogle Scholar
  268. 268.
    Gershoni-Emek N, Altman T, Ionescu A et al (2018) Localization of RNAi machinery to axonal branch points and growth cones is facilitated by mitochondria and is disrupted in ALS. Front Mol Neurosci 11:311.  https://doi.org/10.3389/fnmol.2018.00311 CrossRefPubMedPubMedCentralGoogle Scholar
  269. 269.
    Hoye ML, Regan MR, Jensen LA et al (2018) Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain 141:2561–2575.  https://doi.org/10.1093/brain/awy182 CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Laboratory of Preclinical Research and Environmental Agents, Department of Neurosurgery, M. Mossakowski Medical Research CentrePolish Academy of SciencesWarsawPoland
  2. 2.Department of Cellular Signalling, Mossakowski Medical Research CentrePolish Academy of SciencesWarsawPoland
  3. 3.LSU Neuroscience Center and Departments of Neurology and OphthalmologyLouisiana State University School of MedicineNew OrleansUSA

Personalised recommendations